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RESUMO 
 
 
Epigenética é a área da genética que se foca no estudo das alterações biológicas da 
célula que não envolvem alterações na sequência de nucleótidos do DNA. Um dos 
componentes da epigenética que tem vindo a ganhar interesse na comunidade científica 
são os RNAs longos não codificantes (do inglês long noncoding RNAs - lncRNAs) que 
são transcritos que contém mais de 200 nucleótidos. Estes não possuem quadros de 
leitura abertos (do inglês open reading frames – ORFs) e desempenham papéis 
biológicos importantes em diferenciação celular, pluripotência, regulação da 
transcrição, processamento e tradução de moléculas de RNAs. Têm sido também muito 
associados ao desenvolvimento de cancro, nomeadamente, na progressão tumoral e 
desenvolvimento de metáteses. Várias classes de lncRNAs têm sido descritas tendo em 
conta, maioritariamente, a localização destes transcritos no genoma em relação a 
transcritos com potencial codificante, os RNAs mensageiros (mRNAs). Uma classe de 
lncRNAs com interesse neste projecto é a dos transcritos anti-direccionais naturais (do 
inglês natural antisense transcripts – NAT). Estes transcritos têm a particularidade de 
serem codificados na cadeia anti-direccional de genes que codificam mRNAs, podendo 
haver sobreposição parcial com a região promotora ou com intrões. Pensa-se que 
poderão estar implicados na regulação da transcrição dos genes codificantes de mRNA 
ou na regulação da remoção dos intrões (splicing). 
O presente trabalho é parte de um projecto que tem como objectivo principal 
investigar a biologia dos lncRNAs no contexto do desenvolvimento de leucemia. 
Embora já exista evidências recentes que destacam a importância de lncRNAs na 
regulação da expressão genética, pouco se sabe sobre o seu papel na diferenciação das 
células T e na transformação leucémica. O objectivo final do projecto em si, é encontrar 
possíveis alvos para terapias direccionadas a moléculas de RNA em células 
cancerígenas de Leucemia Linfoblástica Aguda de células T (do inglês T-cell Acute 
Lymphoblastic Leukaemia - T-ALL). A metodologia proposta neste projecto combina 
técnicas de alta resolução de epigenómica, transcriptómica e biologia molecular com 
abordagens para monitorizar a síntese, tempos de semi-vida e localização sub-celular de 
lncRNAs. A análise está focada em precursores de células T primárias purificadas a 
 v 
partir de tumores do timo de ratinho e em modelos celulares de T-ALL de ratinho. O 
factor que diferencia e dá o carácter leucémico a estas células é a sobreexpressão do 
oncogene TLX3 que é considerando um dos genes mais mutados neste tipo de 
leucemias. No entanto, estudos anteriores mostraram que, por si só, esta sobreexpressão 
do oncogene não é suficiente para induzir a T-ALL, deste modo, poderão existir outros 
factores, tais como lncRNA, que estejam envolvidos no desenvolvimento da T-ALL. No 
âmbito deste estudo, foi seleccionado a partir da literatura uma lista de lncRNAs que 
são expressos em células T e podem ser relevantes no contexto da leucemia. 
Para monitorizar o tempo de semi-vida de lncRNAs realizou-se marcação do RNA 
nascente nas células com um pulso de incorporação (do inglês, pulse labelling) do 
análogo do uracilo, 4-thioridine (4sU), que é incorporado em todo o RNA sintetizado na 
célula durante esse pulso de marcação. Segue-se a extracção de todo o RNA da célula e 
purificação dos RNAs nascente marcados com 4sU, e dos pré-existentes e dos não 
marcados. A quantificação por RT-qPCR dos lncRNAs de interesse nas diferentes 
populações de RNA permite o cálculo da semi-vida desses lncRNA. Os resultados 
obtidos neste trabalho corroboram os dados já conhecidos de outras investigações dando 
validade e eficácia da técnica experimental executada. 
Para determinar a localização sub-celular de lncRNAs foi desenvolvido um ensaio 
de hibridação in situ de fluorescência com base em sondas de LNA e amplificação do 
sinal de hibridação das sondas com base em sistemas que utilizam métodos enzimáticos 
associados a fluorescência. Neste caso, os resultados não foram conclusivos, precisando 
esta técnica experimental ser melhorada e optimizada. 
Os lncRNAs que serão analisados por estes ensaios, no futuro, serão fornecidos por 
meio de análise bioinformática do transcritoma de células T em diferentes fases de 
transformação leucémica. No final deste estudo iniciou-se esta análise bioinformática 
com dados de sequenciação de RNA (RNA-seq) obtidos de células T não transformadas 
e de células T em diferentes fases de transformação leucémica Nesta análise pretendeu-
se ter uma ideia geral dos lncRNAs e mRNAs que se encontram diferencialmente 
expressos entre fases diferentes de transformação leucémica. Os resultados preliminares 
desta análise sugerem que existe uma percentagem maior de mRNAs diferencialmente 
expressos do que lncRNAs, quando se comparam células não transformadas com 
células em diferentes fases de transformação leucémica. O objectivo é identificar entre 
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os lncRNAs diferencialmente expressos aqueles que poderão ser relevantes na 
transformação leucémica. Estes serão alvo de estudos funcionais utilizando as técnicas 
optimizadas neste estudo, de modo a que se perceba o seu mecanismo de acção e se 
possa avaliar se têm potencial para ser alvos para terapias direccionadas. 
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ABSTRACT 
 
 
Epigenetics is the field of genetics that studies the alterations in the transcriptional 
potential of a cell without interfering with the DNA sequence. One of its component is 
the long noncoding RNAs (lncRNAs) which are transcripts with more than 200 
nucleotides and no evident open reading frames (ORFs) that play important biological 
roles like transcription and splicing regulation and have been associated with 
carcinogenesis. Several classes of lncRNAs have been described according to their 
genomic location in relation to protein‐coding genes. 
The present work is part of a project aiming at gaining novel insights into the 
biology of lncRNAs in the context of leukemogenesis. Although recent evidence 
highlights the importance of lncRNAs in regulation of gene expression, little is known 
about their role in T-cell differentiation and leukaemic transformation. The ultimate 
goal of the project is finding possible targets for RNA therapeutics in T-cell Acute 
Lymphoblastic Leukaemia (T-ALL). The proposed methodology combines high-
throughput epigenomics, transcriptomics and systems biology approaches with 
techniques to monitor synthesis, lifetime and sub-cellular localization of lncRNAs. The 
analysis is focused on primary T-cell precursors purified from the mouse thymus and on 
cellular mouse models of T-ALL.  
The present study aims to develop functional assays to monitor lifetime and sub-
cellular localization of lncRNAs in a cellular mouse model of T-ALL. To monitor the 
lifetime of lncRNAs we carried out pulse labeling with the uridine analogue 4-thioridine 
(4sU) followed by purification of labeled nascent, pre-existing unlabeled and total 
cellular RNAs. RT-qPCR quantification of the RNA subsets allows the estimation of the 
lncRNA’s half-life. To determine the sub-cellular localization of lncRNAs we 
developed a fluorescence in situ hybridization assay based on LNA probes and enzyme-
based signal amplification. In this study we selected from the literature a list of 
lncRNAs that are expressed in T‐cells and may be relevant in leukemogenisis. The 
candidate lncRNAs that will be analysed by these assays in the future will be provided 
by genome-wide transcriptomic analysis of different stages of T-cell leukemic 
transformation.   
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1. Introduction 
 
 
1.1. The “new” RNA world – Long noncoding RNAs 
 
The general view of the genome and gene regulation in biology has been essential 
centred in protein-coding genes via the central dogma enunciated by Francis Crick in 
1958: RNA is transcribed from DNA and translated into protein (Crick 1970). Since 
then, studies have pointed to the presence of large amounts of RNA that was transcribed 
but did not encode proteins which represents about 80% of the whole genome (Figure 
1.1, A). The characterisation of these noncoding RNAs (ncRNAs) was restricted to a 
few housekeeping genes (including ribosomal RNAs, transfer RNAs and small 
nucleolar RNAs) and to a small number of regulatory RNAs (Rinn & Chang 2012). 
Currently, the number of novel ncRNAs has increased drastically and more is known 
about their function, biogenesis, length, structural and sequence features. According to 
their size, ncRNAs are divided into two major groups: small noncoding RNAs, 
including microRNAs, and long noncoding RNAs (lncRNAs) (Figure 1.1, A and B), 
that are a large and diverse class of transcribed RNA molecules with a length of more 
than 200 nucleotides that resemble messenger RNA in structure and size, but do not 
encode proteins.  Only a relatively small fraction of lncRNAs have been so far 
characterised and we can’t start to classify different types of lncRNA according to their 
functions because we are still far from being able to predict the function of new 
lncRNAs. Nevertheless, from what has already been unravelled they are thought to 
carry out important regulatory functions, adding yet another layer of complexity to our 
understanding of genomic regulation.  
 
 2 
 
Figure 1. 1 – Overview of the coding vs noncoding RNAs in the human genome. (A) Representation of the 
relative percentage of protein-coding and noncoding. (Adapted from Uchida & Dimmeler, 2015) (B) Number of 
noncoding (blue line) and protein coding (red line) annotated on Ensembl until 2013. The x-axis indicates the 
number and the date of the release  (Adapted from Bussotti et al., 2013). 
 
 
1.1.1. Classification of lncRNAs 
 
Long noncoding RNAs (lncRNAs) are generally transcribed by RNA polymerase II 
and undergo co-transcriptional modifications such as capping, polyadenylation and pre-
RNA splicing. They harbour standard canonical splice site signals, but have less exons 
and are generally shorter than mRNAs (Derrien et al. 2012). The predicted open reading 
frames (ORFs) have a poor start codon and ORF contexts, therefore, the translation of 
lncRNAs is not likely to happen (Li & Chen 2013). As such, lncRNAs are defined as 
endogenous cellular noncoding RNA molecules longer than 200 nucleotides in length. 
In summary, they have small coding potential, can be spliced, capped and 
polyadenylated. A major feature is that these transcripts are differential expressed in 
tissues/cells or developmental stages (Bussotti et al. 2013). Some researchers have been 
classifying lncRNA based on their genomic proximity between neighbouring transcripts 
and established six main categories of lncRNAs: (a) intergenic or lincRNA; (b) 
intronic; (c) sense; (d) antisense or NAT (e) Enhancer or eRNA and (f) circular RNA 
(see details in Table 1.1). 
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Table 1. 1 – Classes of long noncoding RNA with their representation and description. In yellow are 
represented protein-coding genes  (Adapted from He et al., 2014; Mattick & Rinn, 2015 and Uchida & Dimmeler, 
2015). 
 
 
 
1.1.2. Function of lncRNAs 
 
The first example of an lncRNA that was characterized as having a function was 
H19, in 1988. This lncRNA was identified as an RNA overexpressed during liver 
development in the mouse. The mouse H19 transcript lacked a large ORF, instead, only 
had small sporadic ORFs that were not evolutionarily conserved, that did not template 
translation in vivo and did not produce a recognizable protein product (Brannan et al. 
1990). One year later, another ncRNA, termed XIST, was found to be expressed 
exclusively from the inactive X chromosome and then demonstrated to be required for 
X inactivation in mammals (Penny et al. 1996). 
Nowadays, a large number of lncRNAs has been described and it’s known that they 
can influence many cellular processes such as spatial conformation of chromosomes, 
chromatin and DNA modifications, RNA transcription, pre-mRNA splicing, mRNA 
degradation, and mRNA translation. It has been reported that they can also produce 
small biological active peptides (see details in Figure 1.2) (Morlando et al. 2015). 
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Figure 1. 2 – Example models of lncRNA functions. Nuclear lncRNAs can regulate transcription by acting as 
enhancer RNA (eRNA) (a), by recruiting chromatin modifying complexes (b), or regulating transcription factors 
activity (c). They can also regulate gene expression by acting on the spatial conformation of chromosomes (d) or 
affecting pre-mRNA splicing (e). mRNA expression can be affected by cytoplasmic lncRNAs which regulate mRNA 
stability (f), mRNA translation (g) and compete with microRNA binding (h). A few lncRNAs contain small open 
reading frames (ORFs) that can be translated in biological active small peptides (i). (Adapted from Morlando et al., 
2015). 
 
One of the most studied lncRNAs is the mammalian Airn (antisense of Igf2r 
noncoding RNA). Airn is located in antisense direction of Igf2r (insulin-like growth 
factor 2 receptor), using a bidirectional promoter. It can influence epigenetic events 
through transcription-dependent mechanisms resulting in the silencing of Igf2r 
transcription (Latos et al. 2012a).  
Another example of lncRNA function can be described by TUG1 (taurine 
upregulated 1) and MALAT1 (meta- stasis associated lung adenocarcinoma transcript 1) 
that are linked to gene activation and repression through the organization of nuclear 
subdomains. These two transcripts bind Polycomb 2, but TUG1 binds methylated 
Polycomb 2 and MALAT1 binds the unmethylated protein. The methylation status of 
Polycomb 2 dictates a switch in both its lncRNA-binding specificity and nuclear sub 
compartment localization. This switch is accompanied by movement of  Polycomb 2 
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target genes between active and repressive nuclear domains and ultimately influences 
downstream gene expression (Yang et al. 2011). 
LncRNAs can also act as regulators of mRNA processing. Nascent pre-mRNAs 
are spliced and processed into one of potentially many isoforms. Alternative splicing 
and editing contribute to the increasing gene isoform diversity (Geisler & Coller 2013). 
LncRNA transcripts that have an antisense orientation to known protein-coding genes, 
also known as natural antisense transcripts (NATs), can influence splicing patterns of 
mRNAs. One example is the Zeb2NAT that interferes with the splicing of ZEB2 (zinc- 
finger E-box binding homeobox 2) pre-mRNA. Zeb2NAT expression inhibits splicing 
of an internal ribosome entry site (IRES)-containing intron. Translation of ZEB2 is 
dependent on this IRES, and therefore, expression of the NAT indirectly enables 
expression of ZEB2 protein (Beltran et al. 2008). ErbAα2 overlapping antisense 
transcript it’s another NAT which its expression controls the alternative splicing of the 
thyroid hormone receptor ErbAα2 mRNA to form two antagonistic isoforms (Sleckman 
et al. 1998). In general, the mechanism by which NATs influence splicing is still 
unclear, but it has been hypothesized to involve splice-site masking and a subsequent 
block in spliceosome recruitment (Faghihi & Wahlestedt 2009). 
MALAT1 (mentioned above), which is an intergenic lncRNA, also affects 
splicing but through a more indirect mechanism. This lncRNA associates with 
interchromatin granules and has been implicated in alternative splicing through the 
modulation of active Ser/Arg splicing factors. Ser/Arg proteins are important regulators 
of alternative splicing and MALAT1 interacts with them and influences the nuclear 
distribution and levels of phosphorylated Ser/Arg proteins. The depletion of MALAT1 
changes the alternative splicing patterns of the pre-mRNAs that they target (Tripathi et 
al. 2010a). 
LncRNAs have also been implicated in nuclear organization through the 
scaffolding of sub-nuclear domains. Both coding and noncoding RNAs have been 
associated in the nucleation of histone locus bodies, paraspeckles and nuclear stress 
bodies. The best-studied lncRNA of this type is NEAT1, which is important for the de 
novo assembly of paraspeckles (sub nuclear domains that may mediate retention of 
hyperedited mRNAs in the nucleus) and this lncRNA is significant for the maintenance 
of these paraspeckles (Mao et al. 2011). 
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1.2. Long noncoding RNAs in Cancer 
 
Cancer causes 20% of deaths in Europe with more than 3 million new cases and 1.7 
million deaths each year. Since the Human Genome Consortium released its final draft 
of the human genome, in 2001, the study of lncRNAs have been strongly associated 
with cancer (Gutschner & Diederichs 2012). LncRNAs are implicated in serial steps of 
cancer development since they can interact with DNA, RNA, protein molecules and/or 
their combinations. Their deregulation confers capacities for tumor initiation, growth, 
and metastasis (Cao 2014).  
Despite the small number of well characterized lncRNAs associated with cancer, 
they already have several possible clinical benefits by offering great potential as novel 
biomarkers for diagnosis, prognosis, metastasis and predicting response to therapy 
(Cheng et al. 2013). For example, overexpression of MALAT1 in small cell lung cancer 
is an indicator of early metastasis and poor prognosis (Gutschner et al. 2013). Other 
studies have been developing a target approach for lncRNAs (Lee 2012). The single-
nucleotide resolution of the sequencing results allows characterization of the structure, 
potential function and disease-associated polymorphisms of the lncRNAs (Li & Chen 
2013). Recent improvement of biological drugs has broadened the types of therapeutic 
targets, which enables strategies targeting RNA molecules (Davis et al. 2010). These 
strategies show promising results for the improvement of lncRNA-based cancer therapy 
(Li & Chen 2013).  
 
 
1.2.1. T-cell differentiation and Leukemogenisis 
 
This work will be focused in one specific type of blood cancer, T-cell Acute 
Lymphoblastic Leukaemia (T-ALL). To understand how this cancer develops, referred 
as leukemogenisis, is important to explain basic concepts of the immune system such as 
T-lymphocyte differentiation.  
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T-lymphocyte differentiation occurs in the thymus and requires the expression of 
several genes in a defined temporal manner. The main characteristic that separate cells 
from different phases of development is the cell surface receptors that are being 
expressed or unexpressed during each state of differentiation. Common lymphoid 
progenitors (CLPs) enter into the thymus through the cortico-medullary junction and 
initiate commitment to the T cell lineage. At this point the cells are called double 
negative (DN) thymocytes because they don’t express CD4+ or CD8+ receptors. The V, 
D, and J gene segments at the TCRβ, TCRγ, TCRδ or TCRα loci determine the 
development into either γδ or αβ T cell lineages. First, the T cell receptor (TCR) β, γ 
and δ loci becomes accessible and begins to be rearrange toward the γδ lineage for the 
expression of the pre-TCR, which helps drive cellular proliferation and leads to the 
CD4
+
8
+
 stage, also called double positive (DP) thymocytes (Sleckman et al. 1998). Pre-
TCR surface expression, referred to as the β-selection process, is marked by arrest of 
TCRβ gene rearrangements and extensive cellular expansion. Afterwards, TCRα locus 
rearrangement leads to the expression of the mature TCR. Signals from the pre-TCR 
allow survival, cellular expansion and further differentiation of T-cells with productive 
rearrangement of the TCRβ (β-selection). The mature TCR, is triggered by its 
interaction with MHC molecules on thymic epithelial cells and allows the selection 
of TCR non-self-reactive thymocytes that recognize self-MHC molecules and the 
production of single positive (SP) mature T-cells (Figure 1.3).  
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Figure 1. 3 – T-cell differentiation process. T-cell differentiation occurs in the thymus where the ordered 
somatic recombination of V, D, and J gene segments at the TCRβ, TCRγ, TCRδ or TCRα loci determine the 
development into either γδ or αβ T cell lineages. Progressive lineage restriction and acquisition of T cell potential 
following migration from the bone marrow to the thymus involve successive differentiation steps defined by the 
acquisition of a number of surface molecules, including CD5, CD1a, CD34, CD3, CD4, and CD8(Adapted from 
Graux et al. 2006). 
 
The TCRα rearrangement is a highly regulated process, in which the TCRα 
enhancer (Eα) plays a primary role (Sleckman et al. 1998). The minimal Eα core 
contains binding sites for three transcription factors (TFs), LEF-1, RUNX1/AML1, and 
ETS1, which have been demonstrated to be crucial for the transcriptional and cis-
chromatin opening activities of the Eα enhanceosome (Dadi et al. 2012). 
Despite the differences between human and mouse thymocyte maturation, they both 
follow the same main developmental stages. Nevertheless, the understanding of the 
different processes and players in T-lymphocyte maturation comes mainly from 
experiments in mice (Graux et al. 2006). 
 
 
1.2.2. T-cell Acute Lymphoblastic Leukemia 
 
T-cell acute lymphoblastic leukaemia (T-ALL) is a blood cancer characterized by an 
uncontrolled increase in the number of immature T lymphocytes. It accounts for 
approximately 15% of paediatric and 25% of adult ALL cases. Even with improved 
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outcome, about 25% of children and 50% of adults still fail to respond to intensive 
chemotherapy protocols (Kalender Atak et al. 2013). The current therapies are highly 
toxic. The patients with primary resistance to chemotherapy and the ones who have 
relapsed after initial treatment have an extremely poor prognosis. In this context, the 
research for novel therapeutic strategies is extremely important (De Keersmaecker et al. 
2014) 
 
 
1.2.3. Genetic alteration related to T-ALL 
 
Oncogenic events in T-ALL include transcriptional activation of proto-oncogenes, 
inactivation of tumor suppressor genes, and activation of signal transduction pathways, 
such as Notch1 pathway by NOTCH1 or FBXW7 mutations (Aifantis et al. 2008). TCR 
chromosomal translocations represent a frequent oncogenic hallmark of T-ALL 
(Cauwelier et al. 2006). This translocations are generally the result from mistakes on the 
V(D)J recombination events that lead to the ectopic activation of oncogenes owing to 
their relocation to the vicinity of potent cis-activating elements within the involved TCR 
locus. 
A specific set of recurrently over-expressed transcription factors (TFs) have been 
documented in T-ALL, including TLX1, TLX3, TAL1, LMO1, HOXA, and NKX 
family members (Van Vlierberghe et al. 2008). T-ALL samples expressing each of these 
transcription factors show a characteristic gene expression signature and as such these 
transcription factors define distinct molecular subtypes in T-ALL (Vlierberghe & 
Ferrando 2012). Point mutations and small insertions/deletions have also been described 
leading to oncogenic events, like mutations that activate NOTCH1 in more than 60% of 
T-ALL cases (Weng et al. 2004), or mutations in cytokine receptors and tyrosine 
kinases such as IL7R and JAK3 (Kalender Atak et al. 2013). 
Oncogenic nucleoporin fusions have been described in diverse types of hematologic 
malignancies, more frequently in acute myeloid leukemia (AML), but also in T-cell 
acute lymphoblastic leukemia (T-ALL) (Takeda & Yaseen 2014). A NUP214-ABL1 
fusion was described in a series of patients with T-ALL (Graux et al. 2004). This fusion 
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is cytogenetically cryptic and is often located in amplified episomes. In T-ALL, 
NUP214-ABL1 is usually associated with rearrangement and/or overexpression of 
TLX1 or TLX3, although, in some patients there are more cells with abnormalities of 
these genes than with NUP214-ABL1, suggesting that the protein fusion is a secondary 
mutation (Graux et al. 2009). 
Overexpression of the orphan homeobox (HOX) proteins TLX1 and TLX3 
represents the most frequent oncogenic event due to chromosomal translocation in 
human T-ALL. TLX1 and TLX3 belong to a subtype of HOX proteins. They contain a 
highly conserved homeodomain (HD) that is known to be involved in DNA and protein-
protein interactions (Holland et al. 2007).  
Physiological expression of TLX1 and TLX3 is restricted to embryonic 
development and no specific function of these genes in the T cell lineage has been 
reported (Vlierberghe & Ferrando 2012). Transgenic expression of human TLX1 in 
mice induces an initial DN2 thymic block followed by development of aneuploid T-
ALL, mitotic checkpoint defects, clonal TCRβ rearrangements, a mostly cortical 
phenotype, and a transcriptional profile similar to that observed in human TLX1+ T-
ALLs (Dadi et al. 2012).  
TLX3 overexpression is a result of the translocation t(5;14)(q35;q32) in 
approximately 25% of pediatric and 5%–10% of adult T-ALL cases (Hatano et al. 
1991). Results have demonstrated that the maturation block observed in TLX+ T-ALLs 
is, in large part, due to ETS1-mediated TLX recruitment to the Eα core, leading to 
repression of Eα and blocked Vα-Jα rearrangement. Failure to express a TCRα gene, 
leads to the arrest development of αβ-committed thymocytes around β-selection, when a 
variety of cell-proliferation signals are likely to be maintained, hence contributing to 
oncogenesis (Figure 1.4). This blockage can be overcome by TLX1/3 abrogation or by 
down-stream TCRαβ expression within an appropriate cellular context. These 
observations have fundamental consequences both for targeted therapy in TLX+ T-
ALLs and for the role of aberrant TCR expression in T lymphoid oncogenesis (Dadi et 
al. 2012). 
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Figure 1. 4 – TLX-Mediated Repression of the TCRa Enhancer. Transcriptional access to the TCRα locus at the 
late double-negative (DN) to CD4+8+ stage is regulated primarily by the function of the Ea enhancer, shown bound 
by its transcriptional activators ETS-1, RUNX1, and LEF1. The onset of Va-Ja recombination begins with 
transcription from the TEA promoter and increased histone acetylation throughout the Jα region. In a subset of T cell 
acute lymphoblastic leukaemia where TLX1 or TLX3 are misexpressed (bottom), ETS-1 can recruit TLX1/3 to Ea and 
this correlates with an enrichment of repressive histone modifications and lack of TCRA gene expression, ultimately 
leading to an arrest in differentiation (Adapted from (King et al. 2012). 
 
 
1.2.1. LncRNA expression during T-cell development and 
differentiation 
 
The knowledge of long non-coding RNAs in immune systems is so far limited. John 
S. Mattick’s group was the first to discover a lncRNAs expressed in CD8+ T cells and 
suggested that many of these transcripts likely play roles in adaptive immunity (Pang et 
al. 2009). There is a well-established role of transcription factors as instructive signals 
for cell differentiation toward a given lineage, however, other features, including 
components of epigenetics, can regulate the maintenance of cellular states (Ranzani et 
al. 2015).  
Several studies have identified an important contribution of lncRNAs to the 
development and function of adaptive immune cells. The analysis of lncRNA 
expression during T-cell development (RNA-seq data from 42 different T-cell types at 
various developmental and differentiation stages) led to the identification of 1,524 
genomic regions expressing lncRNAs that are specific for lineage or developmental 
stage (Hu et al. 2013).  
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Another example is a research focused in studying the expression of lncRNAs in 
CD4
+
 T cells during development and activation. In this study they analyse several 
lncRNAs in different stages of T cell differentiation and compare the expression levels 
between different stages. They found that the expression profiles of lncRNAs in 
different stages of CD4+ were significantly different and that many lncRNAs may exert 
their function through certain mRNAs that play pivotal roles in T-cell development and 
activation. This study  suggests that the expression of lncRNAs can regulate and were 
correlated with the expression of neighbouring mRNAs (Xia et al. 2014). 
Recently, a lncRNA profiling in human T- and B-lymphocytes at different 
differentiation stages identified over 500 previously unknown lncRNAs  (Ranzani et al. 
2015). 
 
 
1.3. Genome research of long noncoding RNAs 
 
LncRNAs are one of the emerging topics in genome research. They can be 
associated with gene regulatory networks, and their deregulation may be involved in a 
large number of complex diseases (Figure 1.5). Taking into account more than 500 
publications, the database of experimentally verified lncRNA-related diseases 
(LncRNADisease) did a short list of 321 lncRNAs that are associated with 221 diseases 
where the most common is cancer (Chen et al. 2013).  
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Figure 1. 5 – Several types of diseases associated with lncRNAs. The number shown for each type of disease is 
the number of lncRNAs found associated with the disease by experimental evidence on interactions‚ epigenetics‚ 
mutation‚ expression‚ and genomic location (Adapted from Nguyen & Caninci 2015). 
 
The screening of lncRNAs for potential therapeutic targets is being developed and 
several lncRNAs have been shown as promising biomarkers in diagnosis and prognosis. 
LncRNAs can be poorly conserved between species, contrasting with protein-coding 
genes and shorter RNAs, which leads to an additional uncertainty about whether a given 
lncRNA is functional. In situ hybridization, genomic, and the perturbation of their 
expression by overexpression and mediated knockdown are important tools to explore 
the roles of lncRNAs (Yan et al. 2012). 
 
 
1.3.1. Expression of lncRNA 
 
Determining under what conditions and in what cells the lncRNAs are expressed 
can provide significant perceptions into their function (Atkinson et al. 2012).  
Studies in mouse and human demonstrated that many lncRNAs are expressed in a 
cell- and tissue-specific manner during development and differentiation, which suggests 
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that they might participate in the regulation of these biological processes (Amaral & 
Mattick 2008).  
RNA sequencing is a good technique to quantify transcripts and enables expression 
levels to be easily compared across different conditions and tissues, without the need for 
complicated normalization methods. An RNA-seq study revealed that 78% lncRNAs are 
expressed as tissue-specific compared to only ∼19% of the coding genes (Cabili MN et 
al. 2011). Another RNA-seq study has analysed the transcriptomes of 102 prostate 
cancer samples, defining 121 lncRNAs whose expression patterns distinguish two 
stages of cancer development (Prensner et al. 2011). Similar RNA-seq studies that 
analyse the dynamic lncRNA expression across different conditions and developmental 
stages in health and disease will provide comprehensive, sensitive and high-resolution 
data of lncRNA expression regulation (Atkinson et al. 2012). 
 
 
1.3.2. Stability of lncRNA 
 
One of the aspects of lncRNAs that is poorly understood is their post-transcriptional 
regulation and their metabolism in the cell. RNA levels within a cell are determined by 
the rates of transcription, RNA processing, and RNA decay (Windhager et al. 2012). 
The general expectation is that lncRNAs are less stable than protein-coding mRNAs due 
to their lower average level of expression and the existence of known unstable classes of 
lncRNAs, however, recent studies have suggested that, like has been seen for mRNAs, 
lncRNAs also have a wide diversity of half-lives (Dinger et al. 2009). The variation in 
lncRNA stability is consistent with their functional diversity and is possible that it is a 
reflection of their complex post-transcription regulation. Actually, post-transcriptional 
regulation seems to be particularly important for lncRNAs because they do not have any 
further translational and post-translational opportunities for regulation like protein-
coding genes have (Clark et al. 2012). 
Metabolic pulse labelling of nascent RNA is a powerful approach to assess the 
kinetics of RNA metabolism and enables the determination of their half-life. Activated 
uridine analogues, like 4-thiouridine (4sU), have been used to measure nascent RNA 
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synthesis and their metabolism at single nucleotide level with high sensitivity 
(Windhager et al. 2012). A genome-wide study using metabolic pulse labelling with a 
uridine analogue have determined similar median half-lives for mRNA and ncRNA 
around 3.4h in HeLa cells (Tani et al. 2012). Another genome-wide study that used 
treatment with actinomicin D, instead of metabolic labelling, to determine transcripts 
half-life reported a median half-life of 3.5h (mean 4.8h) for lncRNAs and 5.1h (mean 
7.7h)  for protein-coding transcripts (Clark et al. 2012). 
 
 
1.3.3. Subcellular localization and single molecule quantification of 
lncRNA 
 
The knowledge of the subcellular localization patterns can provide fundamental 
insights into the biology of lncRNAs and suggest potential molecular roles. Unlike 
mRNAs, which localize manly in the cytoplasm to produce their proteins, lncRNA 
themselves probably localize in their particular site of action, making their location 
within the cell important. A study in human cell lines suggests that ∼30% of lncRNAs 
are found exclusively in the nucleus, ∼15% are found exclusively in the cytoplasm, 
while ∼50% show both nuclear and cytoplasmic localization (Kapranov et al. 2007). 
Sequencing studies cannot discriminate whether an lncRNA localizes in the nucleus or 
cytoplasm, and so there is as yet no systematic categorization of lncRNA localization 
patterns. This feature may be due to the fact that the expression of most lncRNAs tends 
to be lower than mRNA, and so their total abundance is likely far lower, which can 
restrict the number of sites in which a lncRNA may be active (Cabili et al. 2015).  
One hypothesis is that, even with the low average abundance of lncRNAs, a small 
numbers of cells in the population might express high numbers of lncRNA, and this 
could allow an increased number of sites of action in those cells (Dinger et al. 2009). 
RNA fluorescence in situ hybridization (FISH) is a technique that can address these 
questions and propose potential mechanisms for lncRNA activity (Singer & Ward 
1982). One of the best studied lncRNAs is XIST in which RNA FISH demonstrated that 
it accumulates on the inactive X-chromosome (Clemson et al. 1996). Recent examples 
of lncRNAs that were studied by FISH include MALAT1 and NEAT1 which were 
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localized to nuclear bodies (Ip & Nakagawa 2012). However, these examples represent 
highly abundant RNAs in the cell, though, the majority of lncRNAs are considerably 
less expressed, which difficult the use of conventional RNA FISH techniques that have 
quite low sensitivity (Cabili MN et al. 2011). One improvement of conventional RNA 
FISH is the application of single-transcript imaging that allows the validation of 
regulatory interactions. Single-molecule RNA FISH (smRNA-FISH) can provide 
quantitative in situ measurements of a variety of different transcripts and highlight the 
behaviour of the lncRNAs in the specific tissue or cell type that is being analysed. For 
example, in tumor models, single-molecule transcript imaging can enable the 
visualization of transcriptional heterogeneity in tumor progression and the relation 
between spatial context and phenotypic states of cells, represented by their expression 
signatures (Itzkovitz & van Oudenaarden 2011). 
 
 
1.4.  Aims of the Study 
 
Although several lines of recent evidence highlight the importance of lncRNAs in 
regulatory gene expression networks, little is known about their role in T-cell 
differentiation and leukemic transformation. The present work is inserted in a project 
that aims at gaining a novel insight into the biology of lncRNAs in the context of 
leukemogenesis with the ultimate purpose of finding possible transcript targets for RNA 
therapeutics in T‐ALL. To reach this goal the proposed methodology combines high-
throughput epigenomics, transcriptomics and systems biology approaches with 
techniques to monitor synthesis, lifetime and sub-cellular localization of lncRNAs. The 
analysis is focused on primary T-cell precursors purified from the mouse thymus and on 
cellular mouse models of T-ALL. 
The main goal of the present study is to develop functional assays to monitor 
synthesis, lifetime and sub-cellular localization of lncRNAs in a cellular mouse model 
of T-ALL. The candidate lncRNAs that will be analysed by these functional assays will 
be provided by the genome-wide transcriptomic analysis of different stages of T-cell 
leukemic transformation.   
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2. Methodology 
 
 
2.1. Cell culture 
 
The cultured cells used in the work were produced in our collaborators 
laboratory, Pierre Ferrier Lab, in France. In their laboratory, double negative (DN) 
thymocytes were purified from mice’s thymus and transduced with the oncogene TLX3. 
TLX3 encodes a DNA-binding nuclear transcription factor that interacts with the 
transcription factor ETS1 which binds to Enhancer α and leads to maturation arrest (by 
inhibiting TCR rearrangements). The cells transduced with TLX3 were injected in an 
immune-deficient mice that developed T-ALL and the cells obtain from the tumors in 
lymphoid organs, named TAP cells,  were stabilized in cell culture (Figure 2.1) (Dadi et 
al. 2012). We then received frozen TAP cells and cultured them in suspension in RPMI 
1640 medium with 10% fetal bovine serum and 2mM L-glutamine at 37°C and 5% CO2. 
 
 
Figure 2. 1 – Scheme of the T-ALL cell culture model developed by Dadi et al. 2012. Double negative (DN) 
thymocytes were purified from mice’s thymus and transduced with the oncogene TLX3. These cells were then were 
injected in an immune-deficient mice that developed T-ALL and the cells obtain from the tumors were stabilized in a 
immortalized cell culture. 
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2.2. RNA extraction, purification and quantification 
 
Total RNA was extracted from cells using PureZOL (Bio-Rad) followed by DNase I 
treatment (Roche) according to the manufacturer’s instructions. Reverse transcription 
was carried out with the High Fidelity cDNA synthesis Kit (Roche) according to the 
manufacturer’s instructions, using random hexamers. Quantitative real-time PCR 
(qPCR) was performed using iTaqUniversal SYBR Green Supermix (Bio-Rad) in the 
Vii7 Real-Time PCR System (Applied Biosystems). Gene-specific primers are 
presented in Table 1 in the supplementary material. Each sample was run in duplicate. 
The 2
−ΔCt
 method was used to measure the relative changes in transcript levels using 
GAPDH as normalizer.  At least three biological replicates were performed for all target 
RNAs. 
 
 
2.3. DNA extraction, purification and sequencing 
 
For total DNA extraction the cells were washed in PBS, ressuspended in Lysis 
Buffer (50mM Tris-HCl pH8.0; 150mM NaCl; 100mM EDTA; 1% SDS) supplemented 
with 0.1mg/ml of Proteinase K (Sigma) and incubated overnight at 55ºC. The genomic 
DNA was then recovered by phenol/cloroform extraction and ethanol precipitation.  
Standard PCR was performed using NZYLong DNA polymerase (NZYTech) with the 
followed parameters of the thermal cycler: 5 cycles of 5min at 95°C, 1min at 95°C, 
1min3sec at 65°C; 35 cycles of 2min at 68°C, 1min at 68°C, 45sec at 95°C, 45sec at 
65°C; 1 cycle of 1min 30sec at 68°C and 1 cycle of 10min at 68°C.  The primers used to 
amplify and to sequence the PCR products are listed in Table 6.1 in the supplementary 
material. The presence of the PCR products was confirmed by agarose gel 
electrophoresis and the bands purified with High Pure PCR Product Purification Kit 
(Roche) according to the manufacturer’s instructions. The purified PCR products were 
sequenced by STABVIDA (http://www.stabvida.net)  
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2.4. Labelling with 4sU-tagging 
 
To measure transcript stability we carried out pulse labelling with the uridine 
analogue 4-thioridine (4sU) followed by isolation of total cellular RNAs and 
purification of labelled (newly synthesized)  and unlabelled (pre-existing) RNA 
(Windhager et al. 2012) (see scheme of the protocol in Figure 2.2). Exposure of 
eukaryotic cells to 4sU (500μM, 60min) results in its rapid uptake, phosphorylation to 
4sU-triphosphate, and incorporation into newly transcribed RNA. The protocol was 
performed as described by Dölken et al. 2008. Briefly, following isolation of total 
cellular RNA with PureZOL (Bio-Rad), the thiol-labeled RNA was biotinylated using 
EZ-Link Biotin-HPDP (Pierce). The cellular RNA was then quantitatively separated 
into labelled (newly transcribed) and unlabelled (pre-existing) RNA with high purity 
using µMACS streptavidin-coated magnetic beads (Miltenyi) in μMACS columns 
(Miltenyi) placed in an OctoMACS Seperator magnetic stand (Miltenyi). Finally, 
labelled RNA was recovered from the beads by simply adding a reducing agent, 
dithiothreitol (15,4mg/mL) that cleaves the disulphide bond and releases the newly 
transcribed RNA from the beads.  
 
 
Figure 2. 2 – Scheme of the technique of Pulse labeling with 4sU-tagging. 4-thioridine (4sU) is an uridine 
analogue that incorporate the RNA when it’s being synthetized. The separation of the labeled from unlabeled 
transcripts is based on the high affinity of 4sU to biotin (Adapteded from Rädle et al. 2013). 
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The ratios of newly synthesized/total RNA obtain by RT-qPCR after 60minutes 
of incubation with 4sU, allows non-invasive access to precise RNA half-life according 
to the formula given in Figure 2.3 (Rädle et al. 2013). The samples were normalized do 
Gapdh according to its known half-life of 7 hours (Kudla et al. 2006). 
 
 
Figure 2. 3 – Mathematical equation used to determine the transcript half-life developed by Rädle et al. 2013. 
The key factors are the labeling time, which was 60min, and the ratio between newly synthetized and total RNA. 
 
 
2.5. LNA-RNA single-molecule FISH 
 
Fluorescence in situ hybridization (FISH) is a method to detect specific nucleic 
acids in their cellular environment.  The analysis of individual RNAs hybridized with a 
single FISH probe makes possible the counting of an RNA transcript with high spatial 
resolution (Trcek et al. 2012a). Locked nucleic acid (LNA) is a nucleic acid analogue 
that contains at least one nucleotide monomer with a bicyclic furanose ring locked in a 
conformation mimicking RNA (See Figure 2.4).  
 
 
Figure 2. 4 – Representation of the chemical structures of DNA, RNA and locked nucleic acid (LNA) nucleotide 
units (Adapted from Astakhova 2014). 
 
LNA probes provide better specificity and sensitivity and have demonstrate 
much higher thermal stability and higher melting temperatures when hybridized with 
target RNA sequences compared to unmodified counterparts (Vester & Wengel 2004). 
In this work we used one LNA probe for each transcript. The probes were labelled at the 
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5’end with either biotin, for mRNA detection, or digoxigenin for lncRNAs detection. 
The sequences are listed in Table 6.7 in the supplementary material. 
For hybridization the cells were allowed to adhere onto poly-L-lysine coated 
coverslips, washed with PBS and fixed with 3.7% PFA/5% acetic acid/1xPBS for 15 
min at room temperature (RT). Following fixation the cells were washed 3x5min at RT 
with 1xPBS/2mM VRC permeabilized in 75% ethanol and stored at -20ºC in 75% 
ethanol/2mM VRC. Before hybridization the cells were re-hydrated in PBS, digested 
with 0.1% pepsin in 0.01 M HCl with 2mM VRC for 1min at 37ºC and fixed with 3.7% 
PFA/1xPBS for 5 min.  After 3 washes in PBS and a 5 min wash in 2xSSC/0,05% 
Tween20, the cells were hybridized at 55°C (30°C bellow the RNA Tm of the probes) 
for 1 hour with the LNA probes (Exiqon) at 40nM in hybridization mix (50% 
formamide/2xSSC/10% dextran sulphate/50mM sodium phosphate pH7.0. Stringent 
post-hybridisation washes were with 0,1xSSC/0,05% Tween 20 3x5min at 65°C. For 
detection of the hybridized probes the samples were subject to Tyramine Signal 
Amplification (TSA) system or Enzyme-Labeled Florescence (ELF) signal 
amplification system. 
 
 
2.5.1. Tyramine Signal Amplification (TSA) system 
 
TSA system provides enhanced sensitivity of the signal to further detection 
methods. The Horseradish Peroxidase (HRP) reacts with hydrogen peroxide and the 
phenolic part of tyramide produces a quinone-like structure with a radical on the C2 
group, becoming activated. Activated tyramide then rapidly and covalently binds to all 
nearby tyrosine residues with proximity to the initially immobilized HRP site (Figure 
2.6) (Bobrow et al. 1992).  
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Figure 2. 5 – Simplified scheme of TSA system for RNA detection. The LNA probes bind complimentary to the 
sequence of RNA. The 5’ end of the probe was labeled with digoxigenin (DIG) or biotin (BIO). After hybridization 
HRP-conjugated streptavidin or HRP-anti-digoxigenin antibody were added to detect biotin or digoxigenin 
respectively, followed by the HRP substrate Alexa Fluor 546 or Alexa Fluor 647 tyramide (Adapted from Shi et al. 
2012). 
 
In this work the Tyramide Signal Amplification Kit (Molecular Probes® by Life 
Technologies™) was used according to the manufacturer’s instructions. Briefly, the 
cells were incubated in blocking buffer (1% BSA in PBS) for 30 min at room 
temperature. Then HRP-conjugate streptavidin (dilution 1:200 from the stock provided 
in the kit) or HRP-conjugate anti-digoxigenin (Abcam; dilutions tested 1:200, 1:1000 or 
1:2000), both in blocking buffer, was added to the cells and incubated at room 
temperature for 30 min. For the multiple detections, after the first incubation with HRP-
conjugate, HRP was deactivated by incubation with 1%H202 in PBS for 10 min and 
proceeded to the next incubation with the other HRP-conjugate. After three washes in 
1xPBS at 37°C, signals were amplified with labeled tyramide working solution (Alexa 
Fluor 546 or Alexa Fluor 647 tyramide at a 1:100 dilution in amplification 
buffer/0,0015% H2O2) for 10 min. The coverslips were then counterstained in 1mg/ ml 
Hoechst 33342 (Molecular Probes®) for 5 min and mounted in Prolong® Diamond 
Antifade Mountant (Life Technologies™). 
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2.6. Imaging acquisition and analysis 
 
Samples were imaged using a Spinning Disk Confocal Microscope (Zeiss Axio 
Observer) equipped with an Evolve 512 EMCCD camera (Photometrics®) and an 
Yokogawa CSU-x1 confocal scanner (Andor). A Plan-Apochromat 100x oil- immersion 
objective, N.A. 1.40, was used for all imaging experiments. Briefly, after randomly 
selecting cells in a field, a 3D stack viewed image was taken with 0.3mm increments in 
the z-direction and a total of 35 sections.  
 
 
2.7. RNA-seq libraries 
 
RNA samples for Deep sequencing were prepared in Pierre Ferrier’s Laboratory 
(Centre d'Immunologie de Marseille-Luminy, France). Deep sequencing was performed 
by Centro de Análisis Genómico (CNAG), Spain. The sequences obtained from the 
Illumina Genome Analyzer (stranded total RNA-seq with >135M reads) were aligned 
against the mouse genome (mmusculus.9). 
 
 
2.8. Data analysis 
 
The reads alignment to a reference genome was performed with TopHat-Bowtie2 
version 2.0.9. The input arguments used were the mouse genome mmusculus.9, and the 
.fastq files containing the reads from both ends. In order to get only the unique 
alignments for a given read to the reference genome and eliminate the duplicates, the “-
g” parameter was set to 1; “--num-threads” and “--mate-inner-dist” were also changed 
to 4 and 100, respectively, but all the remaining additional default options were left 
unaltered.  
In order to get the fragments per kilobase of exon per million fragments mapped 
(FPKM) values and the differentially expressed genes, the annotation files and the 
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mapped reads were processed by cuffdiff tool using the 1 wild-type samples (RAGZ) 
against the 3 (TL3-1_1, Tumeur7_2 and TAP1B) T-ALL samples. In order to find the 
genes that were up- or downregulated in the samples, the downstream analysis was 
performed with customized scripts in R 3.1.0. The “gene_exp.DIFF” file resulted from 
cuffdiff analysis was filtered to include a false discovery rate (FDR) of 0.05 and a fold 
change of 1.5. 
The differential expression of lncRNAs was obtain by running the RNA-seq data 
against the NONCODE v.4 database (Xie et al. 2014) and for the protein coding gene, 
the analysis was against the UCSC database.  
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3. Results 
 
 
Recent findings have revealed that lncRNAs are implicated in serial steps of cancer 
development. LncRNAs are transcripts with more than 200 nt in length and no evident 
ORFs. These lncRNAs can interact with DNA, RNA and protein molecules acting as 
essential regulators in chromatin organization, transcriptional, splicing and post-
transcriptional regulation. Their differential expression confers the cancer cell capacities 
for tumor initiation, growth, and metastasis (Cao 2014). Despite recent evidence 
highlighting the importance of lncRNAs in regulatory gene expression networks, little is 
known about their role in T-cell differentiation and leukemic transformation. 
The main goal of the project where this work is inserted is to identify and validate 
lncRNAs as potential targets for RNA therapeutics in T cell acute lymphoblastic 
leukaemia (T-ALL). In this present work, we developed a methodology to monitor the 
stability of lncRNA transcripts by metabolic labelling with 4sU (Chapter 3.1) and a 
methodology to visualize the sub-cellular localization of lncRNA/mRNA molecules by 
the use of fluorescence in situ hybridization with LNA oligonucleotidic probes and 
confocal microscopy (Chapter 3.2).  For the purpose of methodology development the 
lncRNA analysed in this study were selected from the literature and their expression in 
the T-ALL cellular model experimentally validated. The candidate lncRNAs that will be 
analysed by these assays in the future will be provided by genome-wide transcriptomic 
analysis of different stages of T-cell leukemic transformation (Chapter 3.3).  
 
 
3.1.  Analysis of lncRNA stability in a T-ALL cellular model 
 
Cellular RNA levels are determined by the interplay of tightly regulated processes 
for RNA transcription and degradation. It has been proposed that the half-life of each 
mRNA is closely related to its physiological function, so it is possible that the RNA 
stability of lncRNAs also reflects their function. Two independent research groups 
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reported that non-coding RNA (ncRNA) half-lives vary over a wide range that is 
comparable with that of mRNAs. In this perspective, ncRNAs with short half-lives may 
have regulatory functions while those with long half-lives could be  involved in 
housekeeping functions (Clark et al. 2012; Tani & Torimura 2013). 
The most widely used method for genome-wide analysis of RNA stability is based 
on the use of transcriptional inhibitors such as actinomycin D (ActD), 5,6-dichloro-1–
D-ribofurano-syl-benzimidazole (DRB) and α-amanitin (α-Am) (Tani & Akimitsu 
2012). ActD inhibits transcription initiation and elongation by intercalating into DNA, 
while DRB and α-Am specifically inhibit RNA Polymerase II-mediated transcription. 
Even though transcriptional inhibitors have been widely used for determining RNA 
stabilities, inhibitor-mediated global transcriptional arrest has a deeply disruptive 
impact on cellular physiology, including splicing and polyA (Tani et al. 2012; Friedel et 
al. 2009). 
4-thiouridine (4sU) has been used to label endogenous RNAs in mammalian cells as 
a non-disruptive technology for measuring RNA decay. 4sU is rapidly taken up by cells 
and after entering a cell, is phosphorylated by cellular uridine kinases. With the use of 
4sU, additional steps, such as electroporation or lipofection, are not necessary for 
labeling RNA and has minimal adverse effects on gene expression (Tani & Akimitsu 
2012). For this reasons we decided to follow this approach to measure the half-lives of 
lncRNAs in T-ALL cells. 
 
 
3.1.1.  Searching the literature for lncRNAs with a potential role in T-
ALL 
 
Before starting to implement the previously describes methodologies in the 
laboratory, we did a search in the literature and databases for lncRNAs that could have a 
relevant function in T-ALL and to be analysed in the study. We started by a review of 
the protein-coding genes that have been reported to be involved in genetic lesions that 
define molecular-genetic subtypes in T-ALL and other recurrent genetic alterations 
(Vlierberghe & Ferrando 2012). We also investigated  lncRNAs that could be expressed 
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in this type of cells using published Chip-seq data (Hu et al. 2013) obtain from T-cell  
and expression levels from the NONCODE database (database for noncoding transcripts 
– http://www.noncode.org/). From this investigation we obtained a list of candidates 
that could be relevant in the context of our cellular model (see tables 3.1 and 3.2). 
 
Table 3. 1 – Genes involved in T-ALL and the the presence of nearby lncRNA. The reads referred in the table 
were obtain by the analysis of Chip-seq data from the study Hu et al. 2013. 
T-ALL 
genes 
Reads of mRNAs in 
mouse’s tymocytes  
Presence of lncRNAs  
Reads of lncRNAs in 
mouse’s tymocytes 
Jak3 ~120 
No lncRNA annotated nearby. At 5’end 
there is a slight antisense signal.. 
<10 
Notch1 ~600 
Has a transcript at its 5’end that overlaps 
the first exon classified as antisense to 
the next gene.  
~134 
Jak1 ~1700 
Has a cluster nearby of intergenic 
lncRNAs. There’s antisense signal. 
~281 
Tal1 <10 No lncRNA annotated nearby.   
Tlx1 <10 
Has an antisense annotated in Ensembl 
(Tlx1os).  
<10 
Tlx3 <10 
Has an antisense annotated in Ensembl 
(Gm12116). 
<10 
Cdkn2a/2b <10 
Has 2 noncoding transcripts (one sense 
and one antisense) 
<10 
Gata3 ~600 
Has an antisense that overlaps a splice 
junction annotated in Ensembl ( 
Gm13256-001). 
~84 
Nup214 ~380 
Has an antisense noncoding transcript, 
ENSMUST00000156387. 
~200-600 
Il7r ~17 
No lncRNA annotated nearby. Has some 
antisense signal in the first exon. 
<10 
Ezh2 ~800 Has an antisense lncRNA annotated. ~70-100 
Zeb2 ~34 Has an antisense lncRNA, Zeb2NAT. <10 
Lyl1 ~11 No lncRNA annotated nearby.  
Bcl11b ~4600 
No lncRNA annotated nearby. Has 
antisense signal. 
~697 
Hoxa13 <10 Has the linRNA Hottip nearby. <10 
Nkx2-5 <10 Has a lincRNA nearby. <10 
Daxx <10 Has an antisense annotated (Ak136742). <10 
Nrip2 <10 Has an antisense annotated (lnc1552). <10 
Fadd ~80 Has an antisense (Faddos). ~12 
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Table 3. 2 – LncRNA candidates. The expression levels referred in the table were taken from the NONCODE data 
base and are represented in FPKMs. 
LncRNA 
Expression in 
mouse’s thymus 
(NONCODE 
database) 
Expression in 
human blood cells 
(NONCODE 
database) 
Function 
Airn 2.61896 0.0250699 
Imprinting at the IGF2R cluster 
(Latos et al. 2012b) 
Hotair 0.0390664 0 
Important factor in the epigenetic 
differentiation of skin (Gezer et al. 
2014) 
Tug1 4.36793 0.55526 
Methylation of Polycomb 2 
(Tani & Torimura 2013) 
Malat1 41.2548 0.011162 
Methylation of Polycomb 2 
and Ser/Arg splicing factor 
regulation 
(Tripathi et al. 2010a) 
Gas5 5.14633 0 
Apoptosis and progression of some 
types of cancer 
(Gezer et al. 2014) 
Neat1 0.506525 0.0842401 
Formation and integrity of nuclear 
paraspeckes 
(Tripathi et al. 2010b) 
Ens91 
(ENSMUST00000130391) 
3.89755 Unknown 
Unknown 
(Xia et al. 2014) 
Ens87 
(ENSMUST00000156387) 
6.9745 Unknown 
Unknown 
(Xia et al. 2014) 
 
We selected the lncRNAs Malat1, Neat1 and Airn because they have been well 
characterized (Cheetham et al. 2013; Fatica & Bozzoni 2014) and are potentially 
expressed in our cell model. We select two other lncRNAs that have not been 
characterized, ENSMUST00000130391 and ENSMUST00000156387 (referred now on 
as Ens91 and Ens87). Ens87 is a lncRNA antisense (NAT) of the protein-coding gene 
Nup214 and was selected from a study where the authors compared different stages of 
T-cell differentiation and this one was reported as being overexpressed in the DN 
thymocytes (Xia et al. 2014), a stage similar to the stage of the TAP cells. From the 
same study, we select Ens91, an intergenic lnRNA that was also upregulated in the DN 
thymocytes. We also choose to analyse Zeb2NAT, the antisense transcript of Zeb2 
because of our interest in studying the dynamics of the mRNA and its correspondent 
NAT. In parallel we analysed the protein-coding genes Nup214, Zeb2 and, as controls, 
Fos, β-actin (β-Act) and Gapdh. 
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3.1.2. Determining lncRNAs/mRNA expression levels by quantitative 
RT-qPCR 
 
There is evidence that lncRNAs are expressed in a cell- and tissue-specific manner 
during development and differentiation (Amaral & Mattick 2008), To determine which 
of the selected RNAs are expressed in our T-ALL cellular model (TAP cells) we 
performed RT-qPCR and  determined their expression levels. The results obtained are 
represented in the graphics of Figure 3.1.  
 
 
Figure 3. 1 – Relative expression levels of selected lncRNAs and mRNAs in TAP cells. Total RNA was purified 
from the cells, reverse transcribed with random primers and analysed by RT-qPCR using ΔCT analysis method. (A) 
Comparison between the expression levels of the different lncRNAs tested. (B) Comparison between the mRNA 
expression levels.(C) and (D) show the differences of the transcript levels between the pairs Nup214/Ens87 and 
Zeb2/Zeb2NAT. The data was normalized to the mRNA Gapdh. The histograms depict mean and standard deviation 
of three independent experiments. The values are listed in Table 6.2 in the supplementary material. 
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The results of the expression levels of the different lncRNAs analysed are 
compatible with the expression values found in the NONCODE database. The results 
show that Malat1 is the most expressed followed by Airn and Neat1 (see Table 3.2). 
The lncRNAs Ens91, Ens87 and Zeb2NAT are all expressed at very low levels in TAP 
cells. When comparing the pairs mRNA/NAT, Nup214/Ens87 and Zeb2/ Zeb2NAT, we 
observe that, in both cases, the mRNA has higher expression levels than its antisense 
transcript. 
 
 
3.1.3. Measuring lncRNA/mRNA half-lives by metabolic labelling 
with 4-Thiouridine 
 
After determining the expression levels of the selected transcripts in TAP cells, we 
proceed our research by establishing the methodology to monitor synthesis and lifetime 
of lncRNAs. We decided to measure the transcripts half-life using an assay based on the 
pulse labeling of nascent transcripts with the uridine analogue 4-thioridine (4sU) 
followed by purification of labeled nascent, pre-existing unlabeled and total cellular 
RNAs. 4sU has the great advantage of having minimal adverse effects on gene 
expression (Tani & Akimitsu 2012). 
TAP cells were incubated with 4sU for 60min followed by purification of total and 
newly transcribed RNA. The separation of the labeled from unlabeled transcripts is 
based on the high affinity of 4sU to biotin. Following purification of the RNA subsets, 
cDNA was synthesized with random-primers and the specific transcripts to be analyzed 
were quantified by RT-qPCR. Values were normalized to Gapdh and half-lives 
calculated using the mathematical equation described previously in the methods section 
(Figure 2.3). This formula takes into account the time of labelling with 4sU, which was 
60 min, and the proportion of the transcript of interest in the newly synthesised RNA 
fraction relative to the total cellular RNA fraction. Additionally, the calculation of the 
transcript’s half-life takes into account the half-life of a second transcript, already 
known, that works as an internal normalizer (norm factor). The values obtain are 
therefore always relative to this other transcript. In this work, we used Gapdh as the 
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normaliser, considering the half-life of 7h described in the literature (Kudla et al. 2006). 
The results obtained are represented in Figure 3.3. 
 
 
Figure 3. 2 – LncRNA and mRNA half-lives determined based on newly transcribed RNA/total RNA ratios. TAP 
cells were incubated with 4sU for 60min. Total and newly transcribed RNA was purified, reverse transcribed with 
random primers and analysed by RT-qPCR. Values were normalized to Gapdh and half-lives calculated as described 
(see formula in Figure 2.3 in the methods section). LncRNAs are represented in the histogram in blue and mRNAs in 
green. The histograms depict mean and standard deviation of three independent experiments. 
 
The results indicate that Malat1 is the most stable lncRNA with a half-life of 4.3h, 
followed by Ens91 that has an half live of around 4h.  The remaining lncRNAs analysed 
have half-lives of 2-3h. Nup214, which is an mRNA, has a half-life of 5,6h and Fos, 
known as a very short lived  mRNA, has an half-life of 1h,which is in agreement with 
what was previously reported (Ross 1995). When comparing the pair Nup214/Ens87, 
mRNA and the corresponding NAT, we observe that the mRNA is more stable (5,6h) 
than the NAT (2,5h). However in the pair Zeb2/Zeb2NAT this difference in half-lives 
was not observed and both have similar and short half-lives (1,9h). 
Even with the small number of targets that we have analysed, we could observe that 
lncRNAs are not typically unstable as a class, but rather show variation in their stability 
profiles in a manner similar to mRNAs, as demonstrated in other studies (Ross 1995; 
Tani et al. 2012). It has been suggested that the large variation in lncRNA stability is 
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consistent with their functional diversity and is likely a reflection of their complex post-
transcription regulation. In fact, post-transcriptional regulation is particularly important 
for lncRNAs because, unlike protein-coding genes, they do not have any further 
translational and post-translational opportunities for regulation (Clark et al. 2012). 
LncRNA expression levels were not correlated with their stability, which could mean 
that lncRNAs below the expression cut-off will not be generally unstable and the same 
for the other way around, although, this possibilities cannot be completely discarded.  
Since lncRNAs do not require translation to produce a functional gene product, it’s 
possible that, especially those acting in the nucleus, can have a function almost 
immediately after transcription and so may not require a long half-life (Dinger et al. 
2009). Moreover, unstable transcripts are very sensitive to changes in the level of 
transcription and respond quickly when transcription changes (Rabani et al. 2011).  
Similarly to mRNA, highly stable lncRNAs may serve ‘‘housekeeping’’ roles 
and also, the fact that they are stable, may suggests that some lncRNAs have evolved to 
avoid degradation through diverse mechanisms, such as secondary structure and 
interactions with RNA-binding proteins (Clark et al. 2012). 
 
 
3.2. In situ detection of individual lncRNA/mRNA molecules using LNA-
modified oligonucleotides 
 
Fluorescence microscopy is currently the best approach to study RNA localization at 
the single-cell level with high spatio-temporal resolution. A variety of recently 
developed FISH techniques make it now possible to track individual RNA molecules in 
single cells (reviewed by Itzkovitz & van Oudenaarden, 2011). Single-molecule RNA 
FISH protocols have been optimized using a set of about 50 short oligonucleotides, each 
one labelled with a single fluorophore (Lyubimova et al. 2013). Alternative protocols 
have been described based on the use of four to ten oligonucleotides about 50nt long 
and labels with 4 or 5 fluorescent dyes (Trcek et al. 2012b). 
In our project, we are establishing a single-molecule RNA FISH (sm-RNA FISH) 
protocol in the cellular mouse model of T-ALL using short oligonucleotide probes with 
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Locked Nucleic Acid (LNA) technology.  The LNA-based oligonucleotide probes have 
a greatly increased hybridization affinity and specificity that enable the detection of 
low-abundance RNAs with the ability to detect single nucleotide mismatches. This has 
been successfully used for in situ localization of microRNAs (Javelle and Timmermans, 
2012) and has great potential for the detection of lncRNAs. However, the use of a single 
LNA probes per target will require signal amplification technology. We decided to  use 
Tyramide Signal Amplification (TSA), which allows several probes to be hybridized 
and detected sequencially with different fluorophors (Shi et al. 2012). 
 
 
3.2.1. Design of LNA-modified FISH probes 
 
Our first goal with the use of sm-RNA FISH is to determine whether the lncRNAs 
remain restricted to the cognate gene locus or accumulate elsewhere in the nucleus. For 
this analysis and to establish the methodology in the laboratory we selected 2 pairs of 
mRNA/NAT: Nup214/Ens87 and Zeb2/Zeb2-NAT. As a positive control in this assay 
we chose to detect β-actin. 
The criteria followed to choose the regions in the transcripts to target with the FISH 
probes were regions without overlap between the mRNA and the corresponding 
antisense lncRNA (NAT) and that were annotated as constitutive exons.  To confirm the 
expression of the selected exons in TAP cells we designed PCR primers to detect those 
exons (Table 6.1 in the supplementary material) and performed RT-qPCR in total RNA 
samples. Some of the primer pairs were design in different exons to enable the detection 
of possible transcript isoforms (see scheme in Figure 3.3 A). The expression results 
obtained for the different regions are shown in Figure 3.3 B and C. 
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Figure 3. 3 – Relative expression levels of selected exons present in the pairs mRNA/NAT (Nup214/Ens87 and 
Zeb2/Zeb2NAT) in TAP cells. Total RNA was purified from the cells, reverse transcribed with random primers and 
analysed by RT-qPCR using ΔCT analysis method. (A) Scheme showing the relative localization of the primers in the 
different transcripts. (B) Comparison between Nup214 and Ens87expression levels using primers for the indicated 
regions. (C) Comparison between Zeb2 and Zeb2NAT expression levels using primers for the indicated regions. The 
data was normalized to the Gapdh mRNA. The histograms depict mean and standard deviation of three independent 
experiments. The values are listed in Table 6.4 in the supplementary material.  
 
The analysis of the expression of Nup214 suggests that exon 33 is not constitutive, 
and in TAP cells is excluded, because amplification of exon 32/33 gives no expression 
and amplification of exon 32/34 gives expression levels similar to exon 32 alone.. This 
suggests that both exon 32 and 34 are present in Nup214 mRNA in TAP cells, but exon 
33 is not. Analysis of the expression of Ens87 indicates that exon 3 is not constitutive 
and is excluded from the spliced Ens87 transcript.  The analysis of the expression of 
Zeb2 gives lower levels when amplifying exon2/4 compared to exon 3/4 or exon4. This 
could be explained by lower efficiency of the amplification of the product exon 2/4 
relative to the others or by the exclusion of exon 2 from Zeb2 mRNA. This data also 
suggests that both exons 3 and 4 are present in Zeb2 mRNA in TAP cells. Relative to 
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the expression analysis of Zeb2NAT we can conclude that exons 2, 3 and 4 are present 
in the spliced transcript. 
From these results we decided design FISH probes complementary to exon 32 of 
Nup214 and to exon 2 of Ens87 to be sure that the regions detected do not overlap and 
the probes detect different transcripts. The same criteria was used for Zeb2 and Zeb2Nat 
where we choose to design FISH probes complementary to exon4 of Zeb2 and exon 4 of 
Zeb2NAT. Because LNA probes are highly specific and fail to hybridize in the presence 
of mismatches we decided sequence the chosen exons before designing the probes. For 
that purpose we amplified the selected exons from genomic DNA extracted from TAP 
cells using the primers listed in Table 6.5 in supplementary material. The amplified 
PCR products were gel purified and send for Sanger sequencing at StabVida 
(http://www.stabvida.com/pt/). The retrieved sequences are given in Table 6.6 of 
supplementary material. The identity was the sequences obtained were confirmed by a 
BLAST analysis in a genomic database.  
We used Exiqon’s Custom LNA™ mRNA/lncRNA Detection Probe design 
tool (www.exiqon.com) to design highly sensitive LNA™ probes specifically targeting 
our  transcripts of interest. To feed the program we used the sequences obtained from 
our own Sanger sequencing of the target region. Taking into account the general probe 
design guidelines provided by Exiqon we chose oligonucleotide modifications at the 
5’end.  We decided to use Biotin modification for the probes that target mRNAs and 
Digoxigenin modification for the probes that target lncRNAs (see Figure 3.4).  
 
 
Figure 3. 4 – Simple scheme representing the regions were the LNA probes bind to the mRNA of Nup214 or 
Zeb2 and its antisense lncRNAs Ens87 or Zeb2NAT, respectively. 
 36 
3.2.2. Detection of lncRNA/mRNA transcripts using single molecule 
LNA-FISH 
 
LNA probes have been successfully used for in situ localization of microRNAs 
(Javelle and Timmermans, 2012) and they also could have great potential for the 
detection of lncRNAs. However, the use of a single LNA probe per target will require 
signal amplification technology. We decided to use Tyramide Signal Amplification 
(TSA) because it is highly sensitive and allows simultaneous detection of multiple 
probes by using sequentially different fluorophores for detection.  
By implementing a single-molecule LNA-RNA FISH approach we can, not only 
determine the sub-cellular localisation of the target transcripts but also determine the 
absolute number of transcripts per cell. Fluorescent FISH signals were detected in a 
spinning disk confocal microscope. Confocal imaging via spinning disk involves 
scanning a field with laser light from a number of pinholes arranged in a pattern on a 
modified Nipkow disk. In the spinning disk confocal the detector is a CCD camera 
which can register the signal from a quarter million or million pixels simultaneously 
with a quantum efficiency of upwards of 90%. The high speed of image acquisition 
combined with the superior sensitivity of high end CCDs makes the spinning disk 
confocal a good system to analyse single-molecule FISH signals.  
First, we evaluated the success of the experiment with a negative and a positive 
control. In the negative control we only add the hybridization buffer with no probes and 
in the positive control we hybridized the cell with β-Actin LNA probe labelled with 
digoxigenin at 5’end, a positive control tested and recommended by the company 
Exiqon. We also tried different concentrations of HRP-conjugate anti-digoxigenin to 
test the technic background (Figure 3.5). 
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Figure 3. 5 – LNA-RNA smFISH in TAP cells, using TSA amplification: Hybridization with β-Actin LNA probe.  
Was performed LNA-RNA smFISH using (a), (c) and (e) hybridization buffer with no probe and (b), (d) and (f) β-
actin probe 5’digoxigenin labelled. The detection was made with TSA signal amplification using HRP-conjugate anti-
digoxigenin at (a) and (b) 1:200 dilution; (c) and (d) 1.1000 dilution and; (e) and (f) 1:2000 dilution. The HRP-
conjugate anti-digoxigenin was detect with Alexa Fluor 546 and imaged with spinning disk confocal microscope, 
objective x100 –oil, with C561 laser. 
 
In all the concentrations used for HRP-conjugate anti-digoxigenin we detect 
differences between the negative and the β-Actin positive control, with the signal of the 
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positive control always higher. We detected cytoplasmic staining for the β-Actin mRNA 
as expected with all the HRP-conjugated anti-digoxigenin dilutions tested. . Comparing 
the different dilutions there is differences in the ratio background/signal and though the 
positive signal of the 1:2000 is higher, the ratio tends to be lower.  The β-Actin signal in 
the 1:1000 dilution is similar to 1:200 dilution, but the negative control has a lower 
background at 1:1000.  It has been described that excess HRP- reagent can result in the 
formation of tyramide dimers that may be deposited in the cells and result in increased 
background. We think that this dimerization of tyramide is the cause of the signals 
observed in the negative control at 1:200 dilution. From the comparison of the signal to 
noise ratio of the different dilutions we concluded that 1:1000 to 1:2000 are appropriate 
and should be used with our custom designed LNA probes.  
 
After this initial optimisation steps and confident that the positive control with the β-
Actin probe is working we performed the LNA-RNA sm-FISH for the other probes. We 
started by the probes that target the lncRNAs Ens87 and Zeb2NAT and that are labelled with 
Digoxigenin at the 5’end. . We decided to use the HRP-conjugate anti-digoxigenin at 1:1000 
dilution. In parallel with the probes we included the negative control, hybridization 
without probe. The results obtained are shown in Figure 3.6. 
 
 
Figure 3. 6 – LNA-RNA smFISH in TAP cells, using TSA amplification: Hybridization with Ens87 and Zeb2NAT 
LNA probes. Was performed LNA-RNA smFISH using (a) hybridization buffer with no probe; (b) Ens87 probe 
5’digoxigenin labelled and; (c) Zeb2NAT probe 5’digoxigenin labelled. The detection was made with TSA signal 
amplification using HRP-conjugate anti-digoxigenin at (a), (b) and (c) 1:1000 dilution. The HRP-conjugate anti-
digoxigenin was detect with Alexa Fluor 546 and imaged with spinning disk confocal microscope, objective x100 –
oil, with C561 laser. 
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Overall the hybridisation with the Ens87 probe tends to give a higher signal than the 
Zeb2NAT probe, which is in agreement with the RT-qPCR expression analysis (see Fig 
3.1 A).  
It is important to refer that, although these results are encouraging they are still 
preliminary. More experiments with different concentrations of probe and HRP-
conjugate anti-digoxigenin should be done to try to improve the signal to noise ratios. 
Additional control to validate the specificity of the signals includes treatment with 
RNase A before the hybridization, which degrade the RNA molecules and should 
eliminate the signal completely. Another control to the specificity of the hybridization 
would be to repeat the hybridisation in different cell types that may not expressed these 
lncRNAs or express them at different levels.  
Finally, we tested the LNA probes that target the mRNAs Nup214 and Zeb2, and 
are labelled with biotin at the 5’end. Also in this case we included the negative control, 
hybridization without probe. The results obtained with this panel of probes are shown in 
Figure 3.7. 
 
 
Figure 3. 7 – LNA-RNA smFISH in TAP cells, using TSA amplification: Hybridization with Nup214 and Zeb2 
LNA probes.  Was performed LNA-RNA smFISH using (a) hybridization buffer with no probe; (b) Nup214 probe 
5’biotin labelled and; (c) Zeb2 probe 5’biotin labelled. The detection was made with TSA signal amplification using 
HRP-conjugate streptavidin at 1:200 dilution. The HRP-conjugate streptavidin was detect with Alexa Fluor 546 and 
imaged with spinning disk confocal microscope, objective x100 –oil, with C561 laser. 
 
In this case our first observation was a much higher background in the negative 
hybridization. A strong cytoplasmic staining was detected which could correspond to 
the detection of endogenous biotin.  It is known that some cells contain high levels of 
endogenous biotin, and this seems to be the case of TAP cells. It is therefore important 
to quench the activity of endogenous biotin which can be achieved with a commercially 
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available Biotin-blocking kit. Only after this optimization step the signal present in the 
Nup214 and Zeb2 hybridizations can be appreciated.  
 
Although the results from the previous experiments still need optimisation we 
decided to try a double hybridisation experiment. In this case, we used the probes for 
the lncRNAs (Ens87 or Zeb2NAT) labelled at 5’end with digoxigenin and the probes 
for the mRNAs (Nup214 or Zeb2) labelled at 5’end with biotin. We hybridized the LNA 
probe pairs mRNA/lncRNA (Nup214/Ens87 or Zeb2/Zeb2NAT) together and then 
detect them consecutively.  Firstly the mRNA probe labelled with biotin was detected 
with HRP-conjugate streptavidin and Alexa Fluor 546 tyramide (green signal) and 
afterwords the HRP was deactivated by incubation with 1%H202 in PBS. Then the 
lncRNA labelled with digoxigenin was detected with HRP-conjugated anti digoxigenin 
and Alexa Fluor 647 tyramide (red signal). In parallel a negative control without probe 
was subjected to the same scheme of detection See results in Figure 3.8 
 
 41 
 
Figure 3. 8 – LNA-RNA smFISH in TAP cells, using TSA amplification: Hybridization with Nup214/Ens87 and 
Zeb2/Zeb2NAT LNA probes LNA-RNA smFISH   was performed using (g), (h) and (i) hybridization buffer with no 
probe; (a), (b) and (c) Ens87 probe 5’digoxigenin labelled and Nup214 probe 5’biotin labelled and; (d), (e) and (f) 
Zeb2NAT probe 5’digoxigenin labelled and Zeb2 probe 5’biotin labelled. The detection was performed with TSA 
signal amplification using HRP-conjugate anti-digoxigenin at 1:1000 dilution and HRP-conjugate streptavidin at 
1:200 dilution. The HRP-conjugate anti-digoxigenin was detect with Alexa Fluor 546 and imaged with spinning disk 
confocal microscope, objective x100 –oil, with C561s laser. The HRP-conjugate streptavidin was detect with Alexa 
Fluor 647 and imaged with spinning disk confocal microscope, objective x100 –oil, with C640s laser. 
 
The signal of the digoxigenin was lost in both cases and the staining with Ens87 and 
Zeb2NAT was similar to the negative control. The staining with Nup214 was also 
similar to the negative control. Since the RT-qPCR indicate that the mRNA are more 
expressed than the lncRNAs, it’s good to try the detection first with HRP-conjugate 
streptavidin and then with HRP-conjugate anti-digoxigenin to avoid losing the signal. 
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Several studies indicate that the majority of lncRNAs are located in nucleus, which 
is consistent with the major function of lncRNA in epigenetic regulation of gene 
expression. There is still a population of lncRNAs that are enriched in cytoplasm and 
have important functions including translational regulation (Derrien et al. 2012).  
Finding a lncRNA primarily in the nucleus near its site of transcription may suggest 
that it regulates transcription of a proximal gene (Cabili et al. 2015). Since genomic 
locations situated in different chromosomes can be in close spatial proximity within the 
nucleus, this proximity would explain the observations of both cis- and trans-mediated 
regulatory effects of lncRNAs. This model could explain how lncRNAs, which are 
generally of lower abundance relative to mRNAs, can reliably identify their target genes 
by searching in spatial proximity near their transcription locus (Rinn & Guttman 2014). 
On the other hand, the lncRNAs that have been identified in the cytoplasm often show 
sequence complementarity with transcripts that originate from either the same 
chromosomal locus or independent loci. It could suggest that upon recognition of the 
target by base pairing, they can modulate translational control (Fatica & Bozzoni 2014). 
It has been suggested that spliced lncRNAs, compared with such un-spliced as single 
exon transcripts, intergenic and cis-antisense RNAs are more stable than those derived 
from introns and with the sub-cellular localization analysis there is indication that the 
location of lncRNAs is widespread in cell, where the nuclear-localized lncRNAs are 
more likely to be unstable (Cao 2014). 
In our work we couldn’t define weather the lncRNAs or the mRNAs tested localized 
in the nucleus or cytoplasm but we expect that with further optimizations of the 
protocols we can achieve that outcome. The correlation of Nup214 with its antisense 
transcript, Ens87, has not yet been described and, in this present study, we investigate a 
possible connection between the mRNA and the NAT. The relation between Zeb2 and 
its NAT (Zeb2NAT) has been highlighted and there is evidence that Zeb2NAT 
interferes with splicing of ZEB2 and that the expression of the NAT indirectly enables 
expression of ZEB2 protein (Beltran et al. 2008). In this work we didn’t observe a 
strong relation with T-ALL but, in another study, performed with a different subtype of 
human T-ALL, where the cells are in a more immature stage, the authors, showed an 
evidence for an oncogenic driver role for ZEB2 through gain-of-function mechanisms 
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where they hypothesized that is possible that the NAT could be involved in the 
overexpression of ZEB2 (Goossens et al. 2015). 
 
 
3.3. Genome-wide analysis of lncRNAs and protein-coding genes in T-cell 
leukemic transformation 
 
High-throughput RNA sequencing (RNA-Seq) has provided useful information for 
lncRNA identification. Nevertheless, the short reads of current technologies still limit 
the ability to accurately delineate full-length transcriptional units, particularly those of 
lncRNAs, which typically are expressed at low levels (Guttman et al. 2009).  
To study genome-wide the differences between diverse stages of T-ALL, strand 
specific RNA-seq from total RNA samples was performed by our collaborators. In our 
analysis, we compare 4 different samples: control sample that correspond to RAG-/- 
thymocytes; TLX3.1 sample that correspond to the cell culture of RAG-/- thymocytes 
transduced with the oncogene TLX3; sample from the tumors formed in the spleen after 
injection in the mouse with TLX3.1 cells and; TAP sample that correspond to the stable 
and immortalized cell culture derived from the T-ALL tumors. 
RNA seq reads were align to the reference mouse genome (mmusculus.9).using 
TopHat and subsequent analysis of differential expression of protein coding and non-
coding genes between the four samples described above was performed by using 
Cuffdiff. To map the aligned reads to annotated coding and non-coding genes were used 
the UCSC and NONODE databases, respectively. 
The results obtain from this analysis are represented in Figure 3.9.  
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Figure 3. 9 – Pie charts of the differential expression of lncRNAs and protein-coding genes. (A) Differential 
expression of lncRNAs between different samples. (B) Differential expression of protein-coding genes between 
different samples.In both cases the reads were align to the genome of reference mmusculus.9 with the TopHat tool 
and the differential expression analysis was obtain by Cuffdiff tool using the NONCODE data base for lncRNAs and 
the UCSC database for the protin-coding genes. The transcript was considered differential expressed if p-
value<0.05. 
 
We could observe that there are more transcripts differentially expressed in the 
analysis of the proteins-coding genes corroborating the evidences that the lncRNAs, 
with less differential expressed transcripts, are more cell- tissue-specific (Amaral & 
Mattick 2008). We also observe a bigger difference of differential expressed transcripts 
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when comparing the samples against the control rather the comparison between each 
sample indicating a close relation that the samples have. 
We also did a close analysis to the lncRNAs and mRNAs tested in the previously 
experiments with the results in Figure3.11. 
 
 
Figure 3. 10 – Differential expression of selected lncRNAs and protein-coding genes. (A) Differential 
expression of lncRNAs between different samples. (B) Differential expression of protein-coding genes between 
different samples.In both cases the reads were align to the genome of reference mmusculus.9 with the TopHat tool 
and the differential expression analysis was obtain by Cuffdiff tool using the NONCODE data base for lncRNAs and 
the UCSC database for the protein-coding genes. The transcript was considered differential expressed if p-
value<0.05. 
 
Based on this analysis Malat1 is not expressed in the control sample and has high 
values in TAP sample which is in agreement with the results from expression obtained 
by RT-qPCR. Neat1 and Airn have decreased expression in relation to control and they 
also corroborate the RT-qPCR results, with Airn more expressed in TAP sample than 
Neat1. Ens91 expression is non-existent and the RT-qPCR also showed a low 
expression. Ens87 has a decreased expression along the sample having a very low 
expression in TAP sample. Zeb2NAT seems to be expressed in the control and the 
tumor sample and, has expected by the RT-qPCR, is very low expressed in TAP 
samples. When looking to the mRNAs, Nup214 doesn’t change significantly between 
the control and the T-ALL samples. Zeb2 has the same behaviour as Zeb2NAT 
corroborating their relationship (Beltran et al. 2008).  
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We also check two new pairs of mRNA/NAT: Fadd/Faddos and Daxx/BC051242. 
Fadd and Daxx are mRNAs that were part of the research done initially when we were 
selecting the lncRNAs to test experimentally (see Table 3.1). Fadd is an adaptor protein 
that bridges members of the tumor necrosis factor receptor superfamily and it’s 
involved in apoptosis (Kim et al. 1996). Daxx is a protein that has been implicated in 
many nuclear processes including transcription and cell cycle regulation (Salomoni and 
Khelifi 2006). The results are represented in Figure 3.11.  
 
 
Figure 3. 11 – Differential expression of new selected pairsmRNA/NAT. (A) Differential expression of lncRNAs 
between different samples. (B) Differential expression of protein-coding genes between different samples.In both 
cases the reads were align to the genome of reference mmusculus.9 with the TopHat tool and the differential 
expression analysis was obtain by Cuffdiff tool using the NONCODE data base for lncRNAs and the UCSC database 
for the protein-coding genes. The transcript was considered differential expressed if p-value<0.05. 
 
Faddos and BC051242 seem both to be upregulated in TAP cells compared to 
normal control. Fadd mRNA, like Nup214, also does not change and Daxx has a similar 
behaviour than its antisense but with less evident changes. The pair Daxx/BC051242 
could be a similar example of mRNA regulation like has been suggested for 
Zeb2/Zeb2NAT. 
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A large amount of sequence data have been generated in the last few years and this 
already allowed the identification of thousands of lncRNAs expressed in different stages 
of hematopoietic development. Nevertheless, most studies merely identify lncRNAs 
without explaining how these molecules act within the cell. This has further generated 
the need to develop new experimental tools to identify and analyse the mechanisms of 
action of lncRNA. Targeted deletion studies in primary cells, or animal models when 
applicable, will be necessary to assess the specific functions of lncRNAs involved in 
normal and malignant hematopoiesis (Morlando et al. 2015). We expect that with 
further analysis of the described datasets we will be able to identify a subset of 
lncRNAs with a role in leukemogenesis. The tool developed in this work will be 
extremely useful to determine the mechanism of action of these lncRNAs and to help 
elucidating their role in the malignant transformation of T-cells.   
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4. Conclusions and Future Work 
 
 
There is a long road ahead in the research of lncRNAs that will require more 
comprehensive transcriptome analyses and transcript assemblies, additional data on 
levels of expression in a specific cell- and tissue-type, and more data on cellular 
localization and interacting partners. We suggest that the annotation of genomes should 
be more transcript centric rather than gene centric, because it has become clear that the 
majority of the transcripts in cells are more than mere intermediates between the 
hereditary information encoded in DNA. In fact, numerous transcripts that  may not be 
translated at all and are involved in critical biological functions (Bussotti et al. 2013; 
Mattick & Rinn 2015). 
Nowadays, cancer therapy has many difficulties, for example, specific targeting of 
cancer cells without interfering with normal tissue function, or specific delivery of 
antitumor drugs may be challenging to the treatment of cancer. LncRNAs could offer a 
number of advantages, both as diagnostic and prognostic markers but also as novel 
specific therapeutic targets. But first, it is necessary to have a detailed knowledge about 
the tumor-specific lncRNA function and its requirement for essential cancer cell 
properties. LncRNAs are interesting targets in cancer therapy and especially their 
cancer- and tissue-specific expression could be a major advantage over other therapeutic 
options (Gutschner & Diederichs 2012). 
In this particular work, the main objectives were the implementation of efficient 
experimental techniques that allow functional analysis of the candidate targets for 
therapy that will be provided after the bioinformatics data analysis of different subsets 
of T-ALL. The knowledge of the stability and geographical information of lncRNAs 
can be essential for its further efficient targeting in the RNA therapeutic context. 
The main goal of this present study is the development and implementation of 
laboratory techniques to measure transcripts half-life by using metabolic pulse labelling 
with 4sU and a novel approach for sub-cellular localization of single RNA molecules 
using a FISH protocol with a single LNA probe per RNA molecule.  
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In the future work, our major objective is to do a more detailed bioinformatics 
analysis of the data that we have with the aim of  finding  potentially relevant lncRNA 
in the process of T-cell malignant transformation that could be used as candidates for  
therapeutic targets for T-ALL. With a list of relevant lncRNAs we will precede for their 
characterization using the experimental techniques developed in this study along other 
in vitro and in vivo assays.   
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6. Supplementary material 
 
 
Table 6. 1 – Primers used in qRT-PCR. Primer3 was used to design the primers and Oligo Calc 
(Oligonucleotide Properties Calculator) to validate them in terms of self-complementarity. BLAST was used to 
validate them in terms of specificity. The primers were synthesised by Invitrogen™. 
Transcript Primers Product length 
- Airn 
Fw:5’GTGGGAGGGATCTTAGCACA’3 
Rv:5’AGAATGGGCTGTGTGTTTCC’3 
114 
- Malat1 
Fw:5’TAAGCGCTTGCCTCTGTCTT’3 
Rv:5’CACCTGCATTCTGTGTGGTC’3 
148 
- Neat1 
Fw:5’TGGGGATTATTGAGCTGAGG’3 
Rv:5’CTCCTGAGTACCGGGATGAA’3 
137 
- Ens91 
Fw:5’TGGGTCTGAAATTCTTGCTTG’3 
Rv:5’GCGATCAGTCATTCCTGTCA’3 
157 
- Ens87 ex2 
Fw:5’GCATGTTCTGCGCTGTGA’3 
Rv:5’CCAGGTCCAGGGTGAAGATA’3 
153 
- Ens87 ex3 
Fw:5’GCATGTTCTGCGCTGTGA’3 
Rv:5’TCAGCATTCCCTCAAGTTCC’3 
214 
- Zeb2NAT ex4 
Fw:5’GGCAGGAGGAAGAAGGAGAA’3 
Rv:5’CCAATCCCTTCAGAGCAAAG’3 
162 
- Zeb2NAT ex2/ex3 
Fw:5’AGAAGGACTTGCTCCCGAAT’3 
Rv:5’TCCTGCCTCCAGACACTCTT’3 
149 
- Nup214 ex32 
Fw:5’TGGAAACAGTGGAGCTAAGACA’3 
Rv:5’CAAAACCTTGGGATGCTACG’3 
113 
- Nup214 e 32/e 33 
Fw:5’TGGAAACAGTGGAGCTAAGACA’3 
Rv:5’ACCCCTCCAAACCCAGGA’3 
207 
- Nup214 ex32/ex34 
Fw:5’TGGAAACAGTGGAGCTAAGACA’3 
Rv:5’ACTGGCGAGGGTACCGAAG’3 
197 
- Zeb2 ex2/e 4 
Fw:5’GAGGCGTAACACGTCAGTCC’3 
Rv:5’GAACTTGGAGAGGGGGTCTT’3 
178 
- Zeb2 ex2/e 3 
Fw:5’TTCCCCTTCTCCAAGTTTTG’3 
Rv:5’GAACTTGGAGAGGGGGTCTT’3 
179 
- Zeb2 ex4 
Fw:5’GTCGCTGTGTTTGGTTGCTA’3 
Rv:5’GTTTTTCCTCCTGGGATTGG’3 
179 
- Fos 
Fw:5’CTTTATCCCCACGGTGACAG’3 
Rv:5’TGACACGGTCTTCACCATTC’3 
172 
- β-Actin 
Fw:5’ CCCTGAAGTACCCCATTGAA’3 
Rv:5’ CTTTTCACGGTTGGCCTTAG’3 158 
- Gapdh 
Fw:5’AACTTTGGCATTGTGGAAGG’3 
Rv:5’ACACATTGGGGGTAGGAACA’3 
357 
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Table 6. 2 – Relative expression levels of selected lncRNAs and mRNAs in TAP cells. Total RNA was purified 
from the cells, reverse transcribed with random primers and analysed by RT-qPCR using the ΔCT analysis method. 
  
#1 #2 #3 #Average Std. Dev. 
LncRNA 
Malat 1 0,06370 0,061299 0,07956 0,068186 0,0080999 
Neat 1 0,00310 0,003429 0,00454 0,003690 0,0006149 
Airn 0,01875 0,025572 0,01931 0,021210 0,0030930 
Ens91 0,00007 0,00006 0,00008 0,000069 0,0000110 
Ens87 (ex2) 0,000233 0,000262 0,000349 0,000281 0,0000490 
Zeb2NAT (ex4) 0,000003 0,000002 0,000002 0,000002 0,0000003 
mRNA 
Nup214 (ex32) 0,010344 0,010996 0,010419 0,010587 0,0002913 
Zeb2 (ex4) 0,000016 0,000015 0,000019 0,000017 0,0000019 
Fos 0,000026 0,000031 0,000034 0,000030 0,0000029 
B-Act 0,860472 0,506874 0,803238 0,723528 0,1549690 
Control Gapdh 1,00000 1,000000 1,00000 1,000000 0,0000000 
 
 
Table 6. 3 – LncRNA half-lives determined based on newly transcribed RNA/total RNA ratios. TAP cells were 
incubated with 4sU for 60min. Total and newly transcribed RNA was purified, reverse transcribed with random 
primers and analysed by RT-qPCR. Values were normalized to Gapdh and the half-lifes calculated as described (see 
formula in Figure 2.3, in methods section). 
 
#1 #2 #3 #Average # Std. Dev. 
Malat 1 4,5 4,1 4,3 4,3 0,163 
Neat 1 2,0 1,9 2,4 2,0 0,232 
Airn 2,9 3,1 2,9 2,9 0,108 
Ens91 3,3 4,1 4,2 4,1 0,397 
Ens87 2,5 2,7 2,4 2,5 0,122 
Zeb2NAT 2,6 1,1 * 1,9 0,749 
Nup214 5,5 5,6 5,9 5,6 0,170 
Zeb2 1,6 3,5 1,9 1,9 0,831 
Fos 0,9 2,2 1,0 1,0 0,589 
B-Act 7,3 * * 7,3 0,000 
Gapdh 7,0 7,0 7,0 7,0 0,000 
 
 
 
 
 
 
 
 57 
Table 6. 4 – Relative expression levels of the pair mRNA/NAT in TAP cells. Total RNA was purified from the 
cells, reverse transcribed with random primers and analysed by RT-qPCR using the ΔCT analysis method. 
 
#1 #2 #3 #Average Std. Dev. 
Ens87 ex2 0,000233 0,000262 0,000349 0,000281 0,0000490 
Ens87 ex2/3 0,000005 0,000005 0,000006 0,000005 0,0000007 
Zeb2NAT ex4 0,000003 0,000002 0,000002 0,000002 0,0000003 
Nup214 ex32 0,010344 0,010996 0,010419 0,010587 0,0002913 
Nup214 ex32/33 0,000026 0,000029 0,000027 0,000027 0,0000011 
Nup214 ex32/34 0,007164 0,008712 0,008650 0,008175 0,0007156 
Zeb2 ex3/4 0,000013 0,000032 0,000023 0,000022 0,0000079 
Zeb2 ex4 0,000016 0,000015 0,000019 0,000017 0,0000019 
Gapdh 1,00000 1,000000 1,00000 1,000000 0,0000000 
 
 
Table 6. 5 – Primers used in standard PCR and DNA sequencing. We used the tools Primer3 to design the 
primers and Oligo Calc (Oligonucleotide Properties Calculator) to validate them. The primers were made by 
Invitrogen™. 
Transcript Primers Product length 
- Ens87  ex2 
Fw:5’CCGTGACTTTGCCAGTTTCT’3 
Rv:5’GGCCAGTGTTGTAGCATTCA’3 
892 
- Zeb2NAT  ex4  
Fw:5’AAGAGTGTCTGGAGGCAGGA’3 
Rv:5’GAAGTGGGCTCTGAATTGGT’3 
1266 
- Zeb2NAT ex2/ex3 
Fw:5’TGGTAAACGACTCAAGTTCCAA’3 
Rv:5’GGGTCTCTCTTCTCTCCCCTAC’3 
1008 
- Nup214 ex32 
Fw:5’ TCCTTGGGTCAGAGAGCAGT’3 
Rv:5’ GCACGTCTTATGTATTAGAAATGCAG’3 713 
- Nup214  ex33 
Fw:5’ ATGGGGCTAGAAAGCAACCT’3 
Rv:5’GCAGTCTTGAGTGGGGGTTA’3 
899 
- Nup214  ex34 
Fw:5’AGGAGTATTTGAGGCCAGCA’3 
Rv:5’TGAGAGCAGAAAGGCAGACA’3 
913 
-  Zeb2  ex4 
Fw:5’GGACCTGCTCCCCACTCT’3 
Rv:5’GCTGGATCGCTTGTTTGTTT’3 
881 
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.Table 6. 6 - DNA Sequences for sm-RNA-LNA FSH probe design. Fragments were obtained by standard PCR 
and sent to StabVida Company for sequencing. 
 
>Nup214_exon32_154nt 
GTGGATGGACCAAGACCTCTGGGAGACCTGCACCTGAGTGTCGGTGATTTCAGACCCAGCATCTGCAGCT
CTGCTGGGCTGTGCCATTGCTCCTGTCCAGAGACTCGGCTGATCTGACTCCTTTCTGTCTTCTGAGCTTCTCCT
ATTCAAGCTCCCTCACACCTGTTCTTGTTCCCTTTAGGATACCTCTAATCTGTTTGGAAACAGTGGAGCTAAGA
CATTTGGAGGGTTTGGCAGCTCATCCTTCGGGGAACAGAAGCCTGCCGGCACATTCAGCTCTGGCGGTGGGA
GCGTAGCATCCCAAGGTTTTGGATTTTCCACTCCAAATAAAACAGGTAACCCGCGAGTGAGCCATGCTCATCT
GTGTGCGTGTGTGAATGACTTGTGAGCTTATAGAAGGTGCCCCTTTGGAGGCAACATC 
 
 
>Ens87_exon2_167nt 
TACTGGAAACTTCTGTCCCTTGAGACGGAGTTTCACACTGTACCCCAGATTGGCCTGGGACTCGGTATGG
CTCACAGACTGGCCTTGAATTTACTGTGACAACTGTCTCCACAAGGAGCAGGCATGTTCTGCGCTGTGACCAG
AGAAATTTCTGATCACTCTGAATCCTGCCAAAAGCCAGTCCATTTGCTGCTGTCTGGGCTCAGCCTTTTCCACT
CCTCTAGACATGACGGCTGGGAATGCAGAGACAGGATTATCTTCACCCTGGACCTGGCTTTGGTTGGTATTTT
ATCAGGTGACATTTTAGACCAGATTGGTGAAGGGTGGCTCTCTGGAGTGAGCATCTAGATGTCCAGGACTATT
CCTGGCTGCCACTTGTCTTGCTGAGTGAGGTCTAGTGAGCTGACCTGACTAGTCCGGTCTCCTCAGGCAGGAG
ACGCACATACCTTGTCTGCAGACGGGCAGGCTTCGTGATAAACAGGGCCCTTGCTCAGAGCATCTGTCCTGGA
AGCCAAAGATTTTTATCTAGAGACCAAGGATGCTGTGTTTGTCTGGGATGGGGCTATTTCTGTGTACAGACAG
GCAGGAAGATAAGAGGAGGGAAAACATCTTTCTGGGTACCATGGTGACAGGGACTTACTGTACCTTTGAAGTC
TTTTATGAGCCTTTGGGGCAGGTGTTTACAGCTCTAAACTTGGGTGTCCCTAATTCTTTTAGTCCAGATATAGC
TCATCATCAAGATGTGGTAAGGAAATGGGGACCCTGCAGGGCAGGGGGCTCCCTGTGAA 
 
 
>Zeb2_exon3_isoform_201_573nt 
GGCTCGGAGACAGATGAAGAGGACAAGCTTCACATTGCTGAAGATGATAGCCTTGCAAACCCTCTGGACC
AGGACACCAGCCCAGCTAGCATGCCCAACCATGAGTCCTCCCCACACATGAGCCAAGGGCTGCTACCAAGAG
AGGAAGAAGAGGAGGAGCTAAGGGAGAGTGTTGTGGAGCACAGCTGGCACAGTGGCGAGATTCTGCAAGCCT
CTGTAGCCGGTCCAGGTAAGTGTCTGTCTGTCCGCCACTGTGTGGCCCCTTCCTGGGCCACCTGCATGTCACC
TGTGCTTCCCAGCAGAACACCTGCAGCCACATCATTCAAATAGTTCTTTCCATCGCCCTTCTGGAGTAGAGAG
CAGAGCTGTTGGCAGATGATGAAGTGATAGCAATGTGGTCACATCACGTACAGTACTCGGATTTTAGGAAATG
ATTGTGTATTGGTTTCAACCCAAGTTGGATATCAACTCTAGTGTAACAAACACAAAACATGAAGTACTTGTACA
TTTTCAATGTGAAACATTACAGAACGCAATCAAGATCTCTACTCTCATGACAGAAAGTATAAAGAA 
 
 
>Zeb2NAT_exon4_368nt 
TTGGATCCCTATATTAAAAGTTTGGCATTTTAATAAAGGGTCTCTAGGTTAACATAGAGCTGTACTATGCT
GGCCAATCTCTGGACCCCTCTACACCTCATGCAGACCACATTACAAAGTGAGGGGACAGGGGCAGGAGGAAG
AAGGAGAAAGGTCAGAGGAACTTAGGACGAAAGAAAGAAGAGGGTGACACTAAACTGTGTGGGGTCTAAGTT
TTGAAGTGCATATTTTTGATATTGCAATTAAACTAAAATTAAAAAGAAAAGACTCCACCTTTGCTCTGAAGGGA
TTGGTTATGCAAATATGGAAGGGATTTCCTGGAGAATACAGCTTTCTACTGTATGGTTAATTAAATAATCACTC
AAAAAGCTTCCAACGTGACGCTTCTGTCGTAATCCAATCAGGTTACATAGGTCCTAAACAAGAAAGATATTTTC
CACATCTGGAAGTCAGCAATTTAGCAAGTACTGCACATTATTAACCAATTCAGAGCCCACTTCCCAGGGGATTT
TTTTTTGAAGTTTAAGTGTTCTTAACCAATGCTCTGCTGTTTTGTTAATCAAAAAGCTGGTTTACACTGCACATA
ATTGGAA 
 
 59 
Table 6. 7 – LNA probes for sm-FISH. The LNA™-enhanced oligonucleotide was produced according to custom 
design by the Exiqon probe design software. The synthesized oligonucleotides were analyzed by High-Performance 
Liquid Chromatography (HPLC) and the identity of the compound was confirmed by Mass Spectrophotometry (MS). 
Target  RNA Probe sequence RNA Tm (°C) 
- β-Actin (positive 
control) 
/5DigN/CTCATTGTAGAAGGTGTGGTGCCA 92 
- Ens87 exon 2  /5DigN/AGGTCCAGGGTGAAGATAAT 83 
- Zeb2NAT exon 4 /5DigN/TTCGTCCTAAGTTCCTCTGA 84 
- Nup214 exon 32 /5Biosg/TCCAAACAGATTAGAGGTAT 83 
- Zeb2  exon 3 /5Biosg/ACAGTGGCGGACAGACAGACA 83 
 
 
Table 6. 8 – Differential expression of lncRNAs between different samples. The reads were aligned to the 
genome of reference mmusculus.9 with the TopHat tool and the differential expression analysis was obtain by 
Cuffdiff tool using the NONCODE data base for lncRNAs. The transcript was considered differential expressed if p-
value<0.05. 
Samples no change Diff. Exp. upregulated downregulated Total 
Control vs TLX3.1 100217 13824 7736 6087 114041 
Control vs Tumour 99797 14244 7107 7143 114041 
Control vs TAP 98403 15638 9200 6440 114043 
TLX3.1 vs Tumour 106288 7753 3677 4080 114041 
TAP vs TLX3.1 106093 7948 3946 4001 114041 
TAP vs Tumour 104295 9746 4513 5232 114041 
      
Samples no change Diff. Exp. upregulated downregulated Total 
Control vs TLX3.1 88% 12% 7% 5% 100% 
Control vs Tumour 88% 12% 6% 6% 100% 
Control vs TAP cells 86% 14% 8% 6% 100% 
TLX3.1 vs Tumour 93% 7% 3% 4% 100% 
TAP vs TLX3.1 93% 7% 3% 4% 100% 
TAP vs Tumour 91% 9% 4% 5% 100% 
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Table 6. 9 – Differential expression of protein-coding genes between different samples. The reads were aligned 
to the genome of reference mmusculus.9 with the TopHat tool and the differential expression analysis was obtain by 
Cuffdiff tool using the UCSC database for the protein-coding genes. The transcript was considered differential 
expressed if p-value<0.05. 
Samples no change Diff. Exp. upregulated downregulated Total 
Control vs TLX3.1 11515 11044 5172 5872 22559 
Control vs Tumour 9432 13127 6518 6609 22559 
Control vs TAP 11981 2037 5512 6469 22559 
TLX3.1 vs Tumour 11607 10952 5841 5111 22559 
TAP vs TLX3.1 12877 9682 4838 4844 22559 
TAP vs Tumour 10554 12005 6499 5506 22559 
      
Samples no change Diff. Exp. upregulated downregulated Total 
Control vs TLX3.1 51% 49% 23% 26% 100% 
Control vs Tumour 42% 58% 29% 29% 100% 
Control vs TAP cells 53% 9% 24% 29% 100% 
TLX3.1 vs Tumour 51% 49% 26% 23% 100% 
TAP vs TLX3.1 57% 43% 21% 21% 100% 
TAP vs Tumour 47% 53% 29% 24% 100% 
 
 
Table 6. 10 – Differential expression of selected lncRNAs between different samples. The reads were aligned to 
the genome of reference mmusculus.9 with the TopHat tool and the differential expression analysis was obtain by 
Cuffdiff tool using the NONCODE data base for lncRNAs. The transcript was considered differential expressed if p-
value<0.05. 
Average Control TLX3.1 Tumor TAP 
Malat1 0 82,0259333 42,3272 93,9326 
Neat1 41,0316333 26,1613167 9,27949667 10,0858 
Airn 23,9768 7,41208167 6,63468167 19,208 
Ens91 0 0 0 0 
Ens87 6,39245667 3,31799536 1,39993056 0,00164 
Zeb2NAT 11,7327 0 15,4999167 0 
Faddos 5,40129 11,6305033 33,4839333 31,4905 
BC051242 10,7931333 27,01235 4,04176 72,2588 
          
Stand.Dev. Control TLX3.1 Tumor TAP 
Malat1 0 7,88610068 5,81430885 5,99472 
Neat1 0,56617798 1,89776271 0,98333134 0,62321 
Airn 0,33070038 0,55077791 0,79130909 1,72405 
Ens91 0 0 0 0 
Ens87 0,08817048 3,33346803 1,40779165 0,00015 
Zeb2NAT 0,16181875 0 1,75480227 0 
Faddos 0,07450164 1,64682478 3,29510136 2,49049 
BC051242 0,14897589 4,22687759 1,23839727 5,39096 
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Table 6. 11 – Differential expression of selected protein-coding genes between different samples. The reads 
were aligned to the genome of reference mmusculus.9 with the TopHat tool and the differential expression analysis 
was obtain by Cuffdiff tool using the UCSC database for the protein-coding genes. The transcript was considered 
differential expressed if p-value<0.05. 
Average Control TLX3.1 Tumor TAP 
Nup214 12,6077667 13,4363333 12,4848667 13,9157 
Zeb2 11,8948 0,03936613 12,5695167 0,00539 
Fadd 4,13448667 4,87612 5,58560167 4,40808 
Daxx 29,1951667 31,3134167 18,4181833 20,7008 
          
Stand.Dev. Control TLX3.1 Tumor TAP 
Nup214 0,55160373 0,49483026 0,42133921 0,58727 
Zeb2 0,52041171 0,00339548 0,40491831 0,00087 
Fadd 0,1808927 0,20610972 0,25336436 0,19814 
Daxx 1,27735342 1,07188539 0,69725356 0,87271 
 
 
